Myriad Genetics (MYGN) 10-K 13 Aug 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Aug. 01, 2014	Dec. 31, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'MYGN	'	'
Entity Registrant Name	'MYRIAD GENETICS INC	'	'
Entity Central Index Key	'0000899923	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	72,795,117	'
Entity Public Float	'	'	$1,547,653,605

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$64,821	$104,073
Marketable investment securities	121,641	268,243
Prepaid expenses	6,921	956
Inventory	23,919	5,007
Trade accounts receivable, less allowance for doubtful accounts of $8,968 in 2014 and $7,500 in 2013	81,297	94,333
Deferred taxes	6,445	8,007
Prepaid taxes	13,609	728
Other receivables	3,770	2,645
Total current assets	322,423	483,992
Equipment and leasehold improvements:	'	'
Equipment	80,685	65,903
Leasehold improvements	18,922	18,294
Gross equipment and leasehold improvements	99,607	84,197
Less accumulated depreciation	65,013	56,595
Net equipment and leasehold improvements	34,594	27,602
Long-term marketable investment securities	84,124	158,748
Long-term deferred taxes	3,180	28,632
Note receivable	'	21,667
Other assets	5,000	13,000
Intangibles, net	205,312	13,330
Goodwill	169,181	56,850
Total assets	823,814	803,821
Current liabilities:	'	'
Accounts payable	23,078	18,132
Accrued liabilities	56,410	44,334
Deferred revenue	1,090	2,043
Total current liabilities	80,578	64,509
Unrecognized tax benefits	24,238	10,718
Total liabilities	104,816	75,227
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value, authorized 5,000 shares; no shares issued and outstanding	'	'
Common stock, $0.01 par value, authorized 150,000 shares; issued and outstanding 73,497 shares in 2014 and 80,577 shares in 2013	735	806
Additional paid-in capital	717,774	697,346
Accumulated other comprehensive loss	-1,515	-424
Retained earnings	2,004	30,866
Total stockholders' equity	718,998	728,594
Total liabilities and stockholders' equity	$823,814	$803,821

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, except Per Share data, unless otherwise specified
Allowance for doubtful accounts	$8,968	$7,500
Preferred stock, par value	$0.01	$0.01
Preferred stock, authorized	5,000	5,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, authorized	150,000	150,000
Common stock, issued	73,497	80,577
Common stock, outstanding	73,497	80,577

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Molecular diagnostic testing	$748,198	$582,392	$472,390
Pharmaceutical and clinical services	30,018	30,773	23,615
Total revenue	778,216	613,165	496,005
Costs and expenses:	'	'	'
Cost of molecular diagnostic testing	96,140	64,376	51,452
Cost of pharmaceutical and clinical services	13,061	15,242	13,207
Research and development expense	67,476	53,706	42,645
Selling, general, and administrative expense	327,097	251,839	208,383
Total costs and expenses	503,774	385,163	315,687
Operating income	274,442	228,002	180,318
Other income (expense):	'	'	'
Interest income	5,397	5,497	4,629
Other	-1,974	-223	-407
Total other income (expense):	3,423	5,274	4,222
Income before income taxes	277,865	233,276	184,540
Income tax provision	101,640	86,137	72,389
Net income	176,225	147,139	112,151
Earnings per share:	'	'	'
Basic	$2.33	$1.82	$1.33
Diluted	$2.25	$1.77	$1.30
Weighted average shares outstanding:	'	'	'
Basic	75,728	80,948	84,608
Diluted	78,182	83,327	86,465
Net income	176,225	147,139	112,151
Comprehensive income:	'	'	'
Unrealized gain (loss) on available-for-sale securities, net of tax	610	-257	-135
Change in foreign currency translation adjustment, net of tax	-1,701	-5	-178
Comprehensive income	$175,134	$146,877	$111,838

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive income (loss)	Retained Earnings (accumulated deficit)
In Thousands
Ending Balance at Jun. 30, 2011	$566,792	$862	$604,409	$151	($38,630)
Ending Balance (in shares) at Jun. 30, 2011	'	86,244	'	'	'
Issuance of common stock for cash upon exercise of options and employee stock purchase plan (in shares)	'	2,013	'	'	'
Issuance of common stock for cash upon exercise of options and employee stock purchase plan	25,029	21	25,008	'	'
Share-based payment expense	26,275	'	26,275	'	'
Stock-based compensation tax benefits	34,193	'	34,193	'	'
Repurchase and retirement of common stock (in shares)	'	-5,688	'	'	'
Repurchase and retirement of common stock	-128,467	-57	-42,205	'	-86,205
Net income	112,151	'	'	'	112,151
Other comprehensive income, net of tax	-313	'	'	-313	'
Ending Balance at Jun. 30, 2012	635,660	826	647,680	-162	-12,684
Ending Balance (in shares) at Jun. 30, 2012	'	82,569	'	'	'
Issuance of common stock for cash upon exercise of options and employee stock purchase plan (in shares)	'	3,640	'	'	'
Issuance of common stock for cash upon exercise of options and employee stock purchase plan	57,825	36	57,789	'	'
Share-based payment expense	26,612	'	26,612	'	'
Stock-based compensation tax benefits	7,888	'	7,888	'	'
Repurchase and retirement of common stock (in shares)	'	-5,632	'	'	'
Repurchase and retirement of common stock	-146,268	-56	-42,623	'	-103,589
Net income	147,139	'	'	'	147,139
Other comprehensive income, net of tax	-262	'	'	-262	'
Ending Balance at Jun. 30, 2013	728,594	806	697,346	-424	30,866
Ending Balance (in shares) at Jun. 30, 2013	80,577	80,577	'	'	'
Issuance of common stock for cash upon exercise of options and employee stock purchase plan (in shares)	'	3,292	'	'	'
Issuance of common stock for cash upon exercise of options and employee stock purchase plan	64,762	33	64,729	'	'
Share-based payment expense	27,068	'	27,068	'	'
Stock-based compensation tax benefits	11,143	'	11,143	'	'
Repurchase and retirement of common stock (in shares)	'	-10,373	'	'	'
Repurchase and retirement of common stock	-287,703	-104	-82,512	'	-205,087
Net income	176,225	'	'	'	176,225
Other comprehensive income, net of tax	-1,091	'	'	-1,091	'
Ending Balance at Jun. 30, 2014	$718,998	$735	$717,774	($1,515)	$2,004
Ending Balance (in shares) at Jun. 30, 2014	73,497	73,496	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:	'	'	'
Net income	$176,225	$147,139	$112,151
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	13,819	8,889	9,069
Loss on disposition of assets	855	8	194
Share-based compensation expense	27,068	26,612	26,275
Bad debt expense	39,235	33,294	24,742
Non-cash expense related to in-process research and development technology	'	'	750
Impairment of intangible assets	'	1,490	'
Deferred income taxes	8,124	7,469	33,625
Unrecognized tax benefits	-660	710	560
Accreted interest on note receivable	-3,337	-2,667	-2,000
Excess tax benefit from share-based compensation	-11,143	-7,888	-34,193
Gain on sale of marketable investment securities	'	-165	-566
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses	-5,486	757	1,204
Trade accounts receivable	-24,372	-67,185	-34,986
Other receivables	-1,870	-706	-2,312
Inventory	-15,794	6,567	-3,426
Prepaid taxes	-12,881	'	'
Accounts payable	-1,492	7,991	-1,249
Accrued liabilities	3,077	11,562	11,218
Deferred revenue	-1,155	-11	748
Net cash provided by operating activities	190,213	173,866	141,804
Cash flows from investing activities:	'	'	'
Capital expenditures for equipment and leasehold improvements	-14,271	-11,373	-9,408
Acquisition of Crescendo Biosciences, Inc. (see Note 12), net of cash acquired	-223,531	'	'
Acquisition of Rules-Based Medicine, Inc., net of cash acquired	'	'	-799
Purchase of in-process research and development technology	'	'	-750
Purchase of other assets	'	'	-100
Purchase of an acquisition option	'	'	-8,000
Issuance of note receivable (Crescendo)	'	'	-17,000
Equity investment (RainDance)	'	-5,000	'
Purchases of marketable investment securities	-161,764	-443,777	-388,067
Proceeds from maturities and sales marketable investment securities	381,899	384,560	385,236
Net cash used in investing activities	-17,667	-75,590	-38,888
Cash flows from financing activities:	'	'	'
Net proceeds from common stock issued under share-based compensation plans	64,762	57,825	25,029
Excess tax benefit from share-based compensation	11,143	7,888	34,193
Repurchase and retirement of common stock	-287,703	-146,268	-128,467
Net cash used in financing activities	-211,798	-80,555	-69,245
Net increase (decrease) in cash and cash equivalents	-39,252	17,721	33,671
Cash and cash equivalents at beginning of year	104,073	86,352	52,681
Cash and cash equivalents at end of year	64,821	104,073	86,352
Supplemental cash flow information:	'	'	'
Cash paid during the year for income taxes	108,207	80,317	33,382
Non-cash investing and financing activities:	'	'	'
Fair value adjustment on marketable investment securities recorded to stockholders' equity	($362)	$433	($14)

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Organization and Summary of Significant Accounting Policies	'
	-1	Organization and Summary of Significant Accounting Policies
		(a)	Business Description and Basis of Presentation
	Myriad Genetics, Inc. and subsidiaries (collectively, the Company) is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine tests. The Company employs a number of proprietary technologies, including DNA, RNA and protein analysis, that help it to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. The Company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine). The Company currently offers thirteen commercial molecular diagnostic tests, including seven predictive medicine tests, three personalized medicine tests, two prognostic medicine tests and one diagnostic medicine test. The Company also generates revenue by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters is located in Salt Lake City, Utah.
	The consolidated financial statements of the Company are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with U.S. GAAP. Certain reclassifications have been made to prior period amounts to conform to the current period presentation.
		(b)	Marketable Investment Securities
	The Company has classified its marketable investment securities as available-for-sale. Available-for-sale investment securities with remaining maturities of greater than one year are classified as long-term. Available-for-sale investment securities with remaining maturities of less than one year are classified as short-term. Available-for-sale investment securities with remaining maturities of less than three months at the time of purchase are classified as cash equivalents. Marketable securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive (loss) in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned.
	A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against “Other income” when a decline in fair value is determined to be other than temporary. We review several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) our ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended June 30, 2014, 2013 and 2012.
		(c)	Trade Accounts Receivable and Allowance for Doubtful Accounts
	Trade accounts receivable are comprised of amounts due from sales of the Company’s molecular diagnostic tests and pharmaceutical and clinical services and are recorded at the invoiced amount, net of discounts and contractual allowances. The allowance for doubtful accounts is based on the Company’s best estimate of the amount of probable losses in the Company’s existing accounts receivable, which is based on historical write-off experience, customer creditworthiness, facts and circumstances specific to outstanding balances, and payment terms. Account balances are charged against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.
		(d)	Equipment and Leasehold Improvements
	Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from three to fifteen years. Repairs and maintenance costs are charged to expense as incurred. For the years ended June 30, 2014, 2013 and 2012, the Company recorded the depreciation expense as follows:
			Years Ended June 30,
			2014		2013		2012
	(In thousands)
	Depreciation expense		$	9,186	$	7,994	$	7,969
		(e)	Inventory
	Inventories consist of reagents, plates and testing kits. Inventories are stated at the lower of cost or market on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels.
	The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers.
		(f)	Intangible Assets and Other Long-Lived Assets
	Intangible and other assets as of June 30, 2014 and 2013 are comprised of acquired patents and intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life.
	The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In December 2012, the Company notified the licensor of the Company’s OnDose product of the Company’s intent to terminate the license agreement, and as a result, recorded an impairment charge of approximately $1.5 million associated with the purchased license agreement. Other than this $1.5 million impairment charge, the Company concluded there was no impairment of long-lived assets for the years ended June 30, 2014, 2013 and 2012.
		(g)	Goodwill
	The Company has recorded goodwill of $169.2 million from the acquisition of Crescendo Bioscience, Inc. that was completed on February 28, 2014 (see Note 12) and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $112.3 million relates to the Company’s molecular diagnostic segment and $56.9 million related to the Company’s pharmaceutical and clinical services segment. Goodwill is tested for impairment on an annual basis as of April 1 and in the interim by reporting unit if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill was evaluated using a two-step process. The first step involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of the reporting unit exceeds its fair value, the second step of the process involves a comparison of the fair value and the carrying amount of the goodwill of that reporting unit. If the carrying amount of the goodwill of the reporting unit exceeds the fair value of that goodwill, an impairment loss would be recognized in an amount equal to the excess of carrying value over fair value. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.
		(h)	Revenue Recognition
	Molecular diagnostic testing revenue is recognized when persuasive evidence of an agreement exists, results have been communicated to the patient, the fee is fixed or determinable, and collection is reasonably assured. Revenue from the sale of molecular diagnostic tests and related marketing agreements is recorded at the invoiced amount net of any discounts or contractual allowances.
	Pharmaceutical and clinical service revenue is recognized when persuasive evidence of an agreement exists, the fee is fixed and or determinable, when the testing service has been completed and the results of the tests are transferred to the customer, and collectability is reasonably assured. In addition, the Company’s wholly owned subsidiary, Myriad RBM, has received national, state, foreign government and private foundation grants and contracts. Revenue associated with these grants and contracts is recognized in the period in which qualifying costs for the services by the grants and contracts are incurred and the related grant or contract fee is earned.
		(i)	Income Taxes
	The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.
	The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.
		(j)	Earnings Per Share
	Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents outstanding.
	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
	(In thousands)		Years Ended June 30,
			2014		2013		2012
	Denominator:
	Weighted-average shares outstanding used to compute basic EPS			75,728		80,948		84,608
	Effect of dilutive stock options			2,454		2,379		1,857
	Weighted-average shares outstanding and dilutive securities used to compute diluted EPS			78,182		83,327		86,465
	Certain outstanding stock options were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
	(In thousands)		Years Ended June 30,
			2014		2013		2012
	Anti-dilutive options excluded from EPS computation			5,273		5,136		8,585
		(k)	Use of Estimates
	The preparation of the consolidated financial statements in accordance with U.S. GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of fixed assets, valuation allowances for receivables and deferred income tax assets, certain accrued liabilities, share-based compensation and impairment analysis of goodwill and intangible assets. Actual results could differ from those estimates.
		(l)	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, “Revenue from Contracts with Customers.” Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. It is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is not permitted. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. We are currently evaluating the impact, if any, the adoption of this standard will have on our Consolidated Financial Statements.

Marketable_Investment_Securiti

Marketable Investment Securities	12 Months Ended
	Jun. 30, 2014
Marketable Investment Securities	'
	-2	Marketable Investment Securities
	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2014 and 2013 were as follows:
	(In thousands)		Amortized		Gross			Gross			Estimated
			cost		unrealized			unrealized			fair value
					holding			holding
					gains			losses
	At June 30, 2014:
	Cash and cash equivalents:
	Cash		$	45,181	$	—		$	—		$	45,181
	Cash equivalents			19,639		1			—			19,640
	Total cash and cash equivalents			64,820		1			—			64,821
	Available-for-sale:
	Corporate bonds and notes			44,449		36			(11	)		44,474
	Municipal bonds			137,821		334			(3	)		138,152
	Federal agency issues			23,134		12			(7	)		23,139
	Total		$	270,224	$	383		$	(21	)	$	270,586
	(In thousands)		Amortized		Gross			Gross			Estimated
			cost		unrealized			unrealized			fair value
					holding			holding
					gains			losses
	At June 30, 2013:
	Cash and cash equivalents:
	Cash		$	40,412	$	—		$	—		$	40,412
	Cash equivalents			63,653		8			—			63,661
	Total cash and cash equivalents			104,065		8			—			104,073
	Available-for-sale:
	Corporate bonds and notes			71,626		13			(15	)		71,624
	Municipal bonds			251,513		109			(537	)		251,085
	Federal agency issues			104,293		24			(35	)		104,282
	Total		$	531,497	$	154		$	(587	)	$	531,064
	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at June 30, 2014:
	(In thousands)		Amortized		Estimated
			cost		fair value
	Cash		$	45,181	$	45,181
	Cash equivalents			19,639		19,640
	Available-for-sale:
	Due within one year			121,505		121,641
	Due after one year through five years			83,899		84,124
	Due after five years			—		—
	Total		$	270,224	$	270,586
	Debt securities in an unrealized loss position as of June 30, 2014 were not impaired at acquisition and the declines in fair value are not attributed to declines in credit quality. Management believes that it is more likely than not that the securities will be held until a recovery of par value. All securities in an unrealized loss position as of June 30, 2014 and 2013 are debt securities. Debt securities available-for-sale in a gross unrealized loss position as of June 30, 2014 and 2013 are summarized as follows:
			Less than 12 months					More than 12 months					Total
	(In thousands)		Fair		Unrealized			Fair			Unrealized		Fair		Unrealized
			value		losses			value			losses		value		losses
	At June 30, 2014:
	Debt securities:
	Corporate bonds and notes			15,961		(11	)		—			—		15,961		(11	)
	Municipal bonds			8,651		(3	)		—			—		8,651		(3	)
	Federal agency issues			4,993		(7	)		—			—		4,993		(7	)
			$	29,605	$	(21	)	$	—		$	—	$	29,605	$	(21	)
			Less than 12 months					More than 12 months					Total
	(In thousands)		Fair		Unrealized			Fair			Unrealized		Fair		Unrealized
			value		losses			value			losses		value		losses
	At June 30, 2013:
	Debt securities:
	Corporate bonds and notes			30,309		(15	)		—			—		30,309		(15	)
	Municipal bonds			93,992		(538	)		—			—		93,992		(538	)
	Federal agency issues			45,528		(34	)		—			—		45,528		(34	)
			$	169,829	$	(587	)	$	—		$	—	$	169,829	$	(587	)

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
	-3	Fair Value Measurements
	The fair value of the Company’s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
	Level 1—quoted prices in active markets for identical assets and liabilities.
	Level 2— observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
	Level 3—unobservable inputs.
	The substantial majority of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. The following table sets forth the fair value of the Company’s financial assets that are re-measured on a regular basis:
	(In thousands)		Level 1		Level 2		Level 3		Total
	at June 30, 2014
	Money market funds (a)		$	13,634	$	—	$	—	$	13,634
	Corporate bonds and notes			—		44,474		—		44,474
	Municipal bonds			—		144,158		—		144,158
	Federal agency issues			—		23,139		—		23,139
	Total		$	13,634	$	211,771	$	—	$	225,405
	(In thousands)		Level 1		Level 2		Level 3		Total
	at June 30, 2013
	Money market funds (a)		$	12,691	$	—	$	—	$	12,691
	Corporate bonds and notes			—		71,624		—		71,624
	Municipal bonds			—		302,055		—		302,055
	Federal agency issues			—		104,282		—		104,282
	Total		$	12,691	$	477,961	$	—	$	490,652
		(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest
	The Company’s Level 1 assets include money market instruments. Level 2 assets consist of marketable investment securities that include federal agency issues, commercial paper, corporate bonds, and municipal bonds. Level 2 securities are valued based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. As of June 30, 2014 and 2013, the Company had no investments which were measured using unobservable (Level 3) inputs.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets	'
	-4	Goodwill and Other Intangible Assets
	Goodwill
	At June 30, 2014, the Company had goodwill of $169.2 million recorded as a result of the acquisition of Crescendo Bioscience, Inc. (“Crescendo”) on February 28, 2014 (see Note 12) and Rules-Based Medicine, Inc. (“Myriad RBM”) on May 31, 2011. The Company assessed goodwill for impairment in accordance with the appropriate guidance (see Note 1(g)) and recorded no impairment of goodwill for the period ended June 30, 2014. The following summarizes changes to the goodwill balance for the years ended June 30, 2014 and 2013:
			Year Ended June 30,
	(In thousands)		2014		2013
	Balance at beginning of period		$	56,850	$	56,850
	Current period acquisitions			112,331		—
	Balance at end of period		$	169,181	$	56,850
	Intangible Assets
	Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, developed technology, a laboratory database, trademarks, and customer relationships as well as non-amortizable intangible assets of in-process technologies, research and development. Certain of these intangible assets were recorded as part of the Company’s purchase of Crescendo on February 28, 2014 (see Note 12) and Myriad RBM on May 31, 2011. The Company’s developed technology and database acquired in conjunction with the purchase of Crescendo have estimated remaining useful lives of 18 years. Trademarks acquired in conjunction with the purchase of Myriad RBM have an estimated remaining useful life of approximately 14 years and customer relationships have an estimated remaining useful life of approximately 7 years. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets and the classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned.
	In December 2012, the Company notified the licensor of the Company’s OnDose product of the Company’s intent to terminate the license agreement, and as a result, recorded an impairment charge of approximately $1.5 million associated with the purchased license agreement. The fair value was estimated for the license agreement using the undiscounted future cash flows method, under which the Company determined that the fair value was less than the carrying value. The impairment is included in research and development in the condensed consolidated statement of comprehensive income and is part of the molecular diagnostic segment. The following summarizes the amounts reported as intangible assets:
	(In thousands)		Gross		Accumulated			Net
			Carrying		Amortization
			Amount
	at June 30, 2014
	Purchased licenses and technologies		$	201,100	$	(6,597	)	$	194,503
	Customer relationships			4,650		(1,441	)		3,209
	Trademarks			3,000		(200	)		2,800
	Total amortized intangible assets			208,750		(8,238	)		200,512
	In-process research and development			4,800		—			4,800
	Total unamortized intangible assets			4,800		—			4,800
	Total intangible assets		$	213,550	$	(8,238	)	$	205,312
	(In thousands)		Gross		Accumulated			Net
			Carrying		Amortization
			Amount
	at June 30, 2013
	Purchased licenses and technologies		$	4,500	$	(2,644	)	$	1,856
	Customer relationships			4,650		(976	)		3,674
	Trademarks			3,000		—			3,000
	Total amortized intangible assets			12,150		(3,620	)		8,530
	In-process research and development			4,800		—			4,800
	Total unamortized intangible assets			4,800		—			4,800
	Total intangible assets		$	16,950	$	(3,620	)	$	13,330
	As of June 30, 2014 the weighted average remaining amortization period for purchased licenses and technologies, trademarks, and customer relationships is approximately 17 years.
	The Company recorded amortization during the respective periods for these intangible assets as follows:
			Years Ended June 30,
	(In thousands)		2014		2013			2012
	Amortization on intangible assets		$	4,633	$	895		$	1,100
	Future estimated amortization expense as of June 30, 2014 for the five succeeding fiscal years is as follows:
	(In thousands)
	Fiscal year ending:
	2015		$	11,900
	2016			11,900
	2017			11,900
	2018			11,881
	2019			11,587
			$	59,168

Leases

Leases	12 Months Ended
	Jun. 30, 2014
Leases	'
	-5	Leases
	The Company leases office and laboratory space under five non-cancelable operating leases, with terms that expire between 2017 and 2025 in Salt Lake City, Utah, one cancelable lease for office and laboratory space with a term of five years in Munich, Germany, and two non-cancelable operating leases for Myriad RBM for office and laboratory space that expire between 2017 and 2020 in Austin, Texas and Saranac Lake, New York. The Company also leases office and laboratory space under one non-cancellable operating lease that expires in 2017 in South San Francisco, California for Crescendo. In addition, the Company maintains lease agreements that expire between 2013 and 2018 for administrative offices in Zurich, Switzerland; Paris, France; Madrid, Spain; and Milan, Italy. Furthermore, the Company leases information technology equipment under two non-cancelable leases, with terms that expire in 2016.
	The following is a summary of the Company’s rental expense for the fiscal years reported:
			Years Ended June 30,
	(In thousands)		2014		2013		2012
	Rental expense		$	11,266	$	8,155	$	6,819
	Future minimum lease payments under the Company’s current leases as of June 30, 2014 are as follows:
	(In thousands)
	Fiscal year ending:
	2015		$	11,235
	2016			11,500
	2017			10,828
	2018			6,489
	2019			6,009
	Thereafter			26,191
			$	72,252

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Jun. 30, 2014
Share-Based Compensation	'
	-6	Share-Based Compensation
	The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 5, 2013, the shareholders approved an amendment to the 2010 Plan to set the number of shares available for grant to 3,500,000. As of June 30, 2014, a total of 3,757,381 shares of common stock are reserved for issuance under the 2010 Plan. In addition, as of June 30, 2014, the Company may grant up to 5,005,532 additional shares under the 2010 Plan if options previously granted under the Company’s terminated 2003 Employee, Director and Consultant Option Plan are cancelled or expire in the future without the issuance of shares of common stock by the Company. The exercise price of options granted in 2014, 2013 and 2012 was equivalent to the fair market value of the stock at the date of grant. The number of shares, terms, and vesting periods are determined by the Company’s board of directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant.
	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted-average assumptions used for grants for the fiscal year ended June 30:
			2014		2013	2012
	Risk-free interest rate		1.60%		0.80%	1.00%
	Expected dividend yield		0%		0%	0%
	Expected lives (in years)		4.1 - 4.7		4.2 - 4.7	4.2 - 4.6
	Expected volatility		40%		44%	44%
	Expected option lives and volatilities are based on historical data of the Company and other factors.
	A summary of activity is as follows:
			2014						2013					2012
			Number			Weighted			Number			Weighted		Number			Weighted
			of			average			of			average		of			average
			shares			exercise			shares			exercise		shares			exercise
						price						price					price
	Options outstanding at beginning of year			14,434,970			21.75			15,233,281		$	19.32		14,453,913		$	18.22
	Options granted			3,320,553			26.52			2,957,623			27.09		3,188,160			20.42
	Less:
	Options exercised			(3,122,427	)		19.44			(3,490,495	)		15.65		(1,852,245	)		11.94
	Options canceled or expired			(394,913	)		24.3			(265,439	)		22.26		(556,547	)		21.48
	Options outstanding at end of year			14,238,183			23.3			14,434,970			21.75		15,233,281			19.32
	Options exercisable at end of year			7,149,155			21.9			7,480,472			20.51		8,397,678			18.01
	Options vested and expected to vest			13,374,736			23.12			13,543,852			21.58		14,514,637			19.28
	Weighted average fair value of options granted during the year						10.04						9.87					7.47
	The following table summarizes information about stock options outstanding at June 30, 2014:
			Options outstanding									Options exercisable
	Range of		Number			Weighted			Weighted			Number		Weighted
	exercise		outstanding			average			average			exercisable		average
	prices		at			remaining			exercise			at		exercise
			June 30,			contractual			price			June 30,		price
			2014			life (years)						2014
	$5.89 - 19.47			4,750,203			5.85		$	17.2			3,103,525	$	16.44
	20.01 - 26.49			5,531,296			6.55			25.03			2,064,390		23.14
	26.84 - 30.34			3,929,684			7.09			28.16			1,975,740		29.17
	30.53 - 37.73			27,000			7.18			34.05			5,500		31.11
				14,238,183			6.47						7,149,155		21.9
	Options exercisable at June 30, 2014 had a weighted average remaining contractual life of 5.56 years.
	Share-based compensation expense recognized and included in the consolidated statements of comprehensive income for the fiscal years ended June 30, 2014, 2013 and 2012 was as follows:
			Years Ended June 30,
	(In thousands)		2014			2013			2012
	Cost of molecular diagnostic testing		$	833		$	1,030		$	1,158
	Cost of pharmaceutical and clinical services			317			219			85
	Research and development expense			5,429			3,246			3,350
	Selling, general, and administrative expense			27,418			22,117			21,682
	Total share-based compensation expense		$	33,997		$	26,612		$	26,275
	Total stock-based compensation for the year ended June 30, 2014 included $0.2 million, $2.0 million and $4.7 million in cost of molecular diagnostic testing, research and development and selling, general and administrative expenses, respectively, related to the acceleration of unvested stock options in connection with the acquisition of Crescendo which closed in February 2014 (see Note 12).
	The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans. The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, and aggregate intrinsic value of options that are fully vested is as follows:
	(In thousands)		As of
			June 30, 2014
	Unrecognized share-based compensation cost		$	41,728
	Aggregate intrinsic value of options outstanding		$	222,451
	Aggregate intrinsic value of options fully vested		$	121,659
	The estimated unrecognized share-based compensation cost will be recognized over a weighted-average period of 2.3 years.
	The total intrinsic value of options exercised during 2014, 2013 and 2012 was as follows:
			Years Ended June 30,
	(In thousands)		2014			2013			2012
	Total intrinsic value of options exercised		$	49,379		$	51,785		$	21,575
	The Company had an Employee Stock Purchase Plan that was approved by shareholders in 1995 (the “1995 Purchase Plan”), and subsequently amended, under which 2,000,000 shares of common stock had been authorized. As of December 5, 2012, a total of 1,990,000 shares of common stock had been issued under the 1995 Purchase Plan when it was terminated. On December 5, 2012, following shareholder approval, the Company adopted the 2012 Employee Stock Purchase Plan (the “2012 Purchase Plan”), under which 2,000,000 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At June 30, 2014, a total of 169,000 shares of common stock had been purchased under the 2012 Plan. Shares purchased under and compensation expense associated with the 1995 and 2012 Plans for the years reported are as follows:
			Years Ended June 30,
	(In thousands)		2014			2013			2012
	Shares purchased under the Plans			169			149			161
	Plan compensation expense		$	1,317		$	885		$	892
	The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black-Scholes option-pricing model using the following weighted-average assumptions:
		2014			2013			2012
Risk-free interest rate			0.1	%		0.1	%		0.1	%
Expected dividend yield			0	%		0	%		0	%
Expected lives (in years)			0.5			0.5			0.5
Expected volatility			56	%		37	%		30	%

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
	-7	Stockholders’ Equity
	Stock Repurchase Program
	The Company previously announced the following stock repurchase programs for its common stock:
	Date Authorized		Amount Authorized		Date Completed
	May-10		$	100,000,000	August 2010
	Aug-10		$	100,000,000	February 2011
	Mar-11		$	100,000,000	September 2011
	Aug-11		$	200,000,000	Jan-13
	Feb-13		$	200,000,000	Nov-13
	Nov-13		$	300,000,000	ongoing
	Total:		$	1,000,000,000
	In November 2013, the Company completed its fifth share repurchase program, which authorized the repurchase of up to $200 million of the Company’s common stock. From July 2013 through November 2013, the Company repurchased $153 million worth of shares under this program. In November 2013, the Company’s Board of Directors authorized a sixth share repurchase program of $300 million of the Company’s outstanding common stock. The Company plans to repurchase the $300 million of its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of June 30, 2014, the Company has repurchased $134 million of shares under the current $300 million share repurchase authorization.
	The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to accumulated deficit. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended June 30, 2014, 2013 and 2012 were as follows:
			Year ended June 30,
	(In thousands)		2014		2013		2012
	Shares purchased and retired			10,373		5,632		5,688
	Common stock and additional paid-in-capital reductions		$	82,617	$	42,679	$	42,262
	Charges to retained earnings		$	205,086	$	103,589	$	86,205

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Taxes	'
	-8	Income Taxes
	Income tax expense consists of the following:
			Year ended June 30,
	(In thousands)		2014			2013			2012
	Current:
	Federal		$	97,442		$	80,333		$	67,492
	State			3,541			6,021			4,647
	Total Current			100,983			86,354			72,139
	Deferred:
	Federal			(666	)		660			(2,192	)
	State			746			(431	)		2,326
	Foreign			(2,865	)		(2,051	)		(1,735	)
	Change in valuation allowance			3,442			1,605			1,851
	Total Deferred			657			(217	)		250
	Total income tax expense		$	101,640		$	86,137		$	72,389
	Income (loss) before income taxes consists of the following:
			Year ended June 30,
	(In thousands)		2014			2013			2012
	United States		$	292,081		$	243,556		$	189,702
	Foreign			(14,216	)		(10,280	)		(5,162	)
				277,865			233,276			184,540
	The differences between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated statements of comprehensive income were as follows:
			Year ended June 30,
			2014			2013			2012
	Federal income tax expense at the statutory rate			35	%		35	%		35	%
	State income taxes, net of federal benefit			1.6			1.7			2.7
	Research and development credits, net of the federal tax on state credits			(0.2	)		(1.0	)		(1.3	)
	Uncertain tax positions, net of federal benefit on state positions			(0.1	)		0.2			0.2
	Incentive stock option and employee stock purchase plan expense			(0.3	)		(0.5	)		1
	Change in valuation allowance			1.2			0.7			1
	Basis difference, disposition of foreign subsidiary			(1.9	)		0			0
	Other, net			1.3			0.8			0.6
				36.6	%		36.9	%		39.2	%
	The significant components of the Company’s deferred tax assets and liabilities were comprised of the following at June 30, 2014 and 2013:
			Year ended June 30,
	(In thousands)		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards		$	76,986		$	8,336
	Property, plant and equipment			2,947			3,103
	Accrued vacation			1,551			1,269
	Allowance for doubtful accounts			3,285			2,771
	Stock compensation expense			25,952			21,135
	Capital loss carryover			0			1,424
	Research and development credits			11,207			5,367
	Uncertain state tax positions			555			1,247
	Other, net			312			643
	Total gross deferred tax assets			122,795			45,295
	Less valuation allowance			(41,420	)		(8,218	)
	Total deferred tax assets			81,375			37,077
	Deferred tax liabilities:
	Intangible assets			71,750			438
	Total deferred tax liabilities			71,750			438
	Net deferred tax assets			9,625			36,639
	Current net deferred tax asset			6,386			8,007
	Long term net deferred tax asset			3,239			28,632
	Net deferred tax asset		$	9,625		$	36,639
	On February 28, 2104, the Company completed the acquisition of privately-held Crescendo Bioscience, Inc. See Note 12. The Company’s allocation of the purchase consideration included deferred tax assets and liabilities to reflect the difference between financial statement and tax basis of assets and liabilities. Due to the limitations of Internal Revenue Code Sections 382 and 383 related to ownership changes, a significant portion of Crescendo’s deferred tax assets related to net operating losses and research credits are estimated to expire un-utilized. A valuation allowance was established to reflect the estimated expiration of those deferred tax assets. In addition, ASC guidance requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. In accordance with those guidelines, the Company established a liability for unrecognized tax benefits. The components of deferred tax assets, deferred tax liabilities, and the liability for unrecognized tax benefits that were included in the allocation of Crescendo’s purchase consideration are as follows:
	(In thousands)
	Deferred tax assets:
	Net operating loss carryforwards		$	70,048
	Research and development credits			5,815
	Other, net			312
	Total gross deferred tax assets			76,175
Less valuation allowance			(29,760	)
Total deferred tax assets			46,415
Deferred tax liabilities:
Intangible assets			72,005
Stock compensation expense			4,443
Total deferred tax liabilities			76,448
Net deferred tax liability			30,033
Liability for unrecognized tax benefits		$	14,180
Due to sustained positive operating performance and the availability of expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets, a valuation allowance has been established. For the years ended June 30, 2014 and 2013, the Company’s valuation allowance increased by $33,202,000 and $1,605,000, respectively. The increase for the year ended June 30, 2014 consisted of $29,760,000 related to the acquisition of Crescendo and $3,442,000 primarily due to foreign net operating losses, for which the Company concluded it was more likely than not that the benefits of the losses will not be realized. The increase in the year ended June 30, 2013 was primarily due to foreign net operating losses, for which the Company concluded it was more likely than not that the benefits of the losses will not be realized.
For the years ended June 30, 2014 and 2013, the Company realized $7,122,000 and $7,888,000, respectively, of excess tax benefits from stock-based compensation as a reduction of taxes payable. Excess tax benefits from stock based compensation are credited directly to additional paid-in-capital. The Company has adopted the with-and-without tax allocation approach for excess tax benefits, which results in the windfall tax benefits being utilized last after considering all other tax attributes available to the Company.
At June 30, 2014, the Company had the following net operating loss and research credit carryforwards, with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated.
(In thousands)		Amount			Subject to			Expires			through
					sections			beginning
					382, 383			in year
Carryforwards
Federal net operating loss		$	164,504			Yes			2027			2033
Utah net operating loss			229,900			No			2015			2024
California net operating loss			155,834			Yes			2016			2033
Oklahoma net operating loss			14,142			Yes			2023			2033
Foreign net operating losses (various jurisdictions)			27,183			No			Various			Various
Federal research credit			3,250			Yes			2025			2032
Utah research credit			8,296			No			2021			2028
California research credit			2,565			Yes			n/a			n/a
All of the Utah net operating loss carryforwards are ‘excess tax benefits’ as defined by ASC guidance and, if realized in future years, will be recognized as a credit to additional paid-in capital. Approximately $92,557,000 of the Utah net operating loss ‘excess tax benefits’ are attributable to periods prior to adoption of guidance limiting recognition of the deferred tax asset and are included in deferred tax assets (prior to any offset by valuation allowance.) The remaining $137,343,000 of Utah net operating loss ‘excess tax benefits’ are not included in deferred tax assets and will be recognized only upon realization of the tax benefit.
The Company’s deferred tax asset for the Utah net operating loss ‘excess tax benefits’ attributable to periods prior to the adoption of the standard is approximately $3,008,000 and is offset by a full valuation allowance at June 30, 2014. If the ‘excess tax benefits’ are recognized as additional paid-in-capital in future years, the corresponding valuation allowance will be reversed. At June 30, 2014, the Company also has a valuation allowance of $3,786,000 offsetting its foreign net operating loss carryforwards.
The Company incurred a taxable loss of $15,200,000 on the disposition of Psynova, a U.K. corporation, during the fiscal year. The Company’s tax basis in the stock of this subsidiary exceeded its accounting basis. According to ASC guidance, no deferred tax asset is recorded on outside basis differences in a foreign subsidiary when the tax basis exceeds the book basis. Due to the fact that a deferred tax asset had not been previously recorded, the loss on disposition reduces the Company’s effective tax rate and, accordingly, is reflected in the effective rate reconciliation.
Consistent with the indefinite reversal criteria of ASC 740-30-25-17, the Company intends to invest undistributed earnings of its foreign subsidiaries indefinitely. However, due to the cumulative losses that have been incurred to date in its foreign operations, the amount of unrecorded deferred liability due to the indefinite reversal criteria at June 30, 2014 is $0.
In July 2006, the FASB issued ASC Topic 740 Subtopic 10 Section 05, which clarifies the accounting for uncertainty in tax positions. ASC guidance requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The Company adopted the guidance on July 1, 2007 and recorded $0 cumulative effect. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
		Year ended June 30,
(In thousands)		2014			2013			2012
Unrecognized tax benefits at the beginning of year		$	10,918		$	10,208		$	9,648
Gross increases—current year tax positions			1,785			710			560
Gross increases—prior year tax positions			350			—			—
Gross increases—acquisitions			14,180
Gross decreases—prior year tax positions			(2,995	)
Unrecognized tax benefits at end of year		$	24,238		$	10,918		$	10,208
Interest and penalties in year-end balance		$	620		$	270		$	—
Interest and penalties related to uncertain tax positions are included as a component of income tax expense.
The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations. The years ended June 30, 2011 through June 30, 2014 remain subject to examination at June 30, 2014. The Company’s New York State income tax returns for the years ended June 30, 2011, 2012 and 2013 were under examination by the New York State Department of Taxation and Finance. The audit was settled during the year ended June 30, 2014. All amounts due resulting from the New York audit have been paid and are reflected in the current income tax provision. The Company’s New Jersey State income tax returns for the years ended June 30, 2007 through 2013 are currently under examination by the New Jersey State Department of Taxation and Finance. Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued. The Company’s U.S. federal tax return, U.K. income tax return and all other state tax returns are not currently under examination.

Employee_Deferred_Savings_Plan

Employee Deferred Savings Plan	12 Months Ended
	Jun. 30, 2014
Employee Deferred Savings Plan	'
	-9	Employee Deferred Savings Plan
	The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee’s contribution with the employer’s contribution not to exceed 4% of the employee’s compensation. The Company’s recorded contributions to the plan as follows:
			Years ended June 30,
	(In thousands)		2014		2013		2012
	Deferred savings plan Company contributions		$	4,430	$	3,450	$	2,955

Segment_and_Related_Informatio

Segment and Related Information	12 Months Ended
	Jun. 30, 2014
Segment and Related Information	'
	-10	Segment and Related Information
	The Company’s business units have been aggregated into three reportable segments: (i) research, (ii) molecular diagnostics and (iii) pharmaceutical and clinical services, formerly called companion diagnostics. The research segment is focused on the discovery of genes, biomarkers and proteins related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The business of Crescendo acquired in February 2014 is included as part of the molecular diagnostic segment. The pharmaceutical and clinical services segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries.
	The accounting policies of the segments are the same as those described in the summary of significant accounting policies (Note 1). The Company evaluates segment performance based on income (loss) before interest income and other income and expense.
	(In thousands)		Research			Molecular			Pharmaceutical &			Total
						diagnostics			clinical services
	Year ended June 30, 2014:
	Revenues		$	—		$	748,198		$	30,018		$	778,216
	Depreciation and amortization			2,001			9,887			1,931			13,819
	Segment operating income (loss)			(64,981	)		338,020			1,403			274,442
	Year ended June 30, 2013:
	Revenues		$	—		$	582,392		$	30,773		$	613,165
	Depreciation and amortization			2,182			4,974			1,733			8,889
	Segment operating income (loss)			(56,428	)		291,509			(7,079	)		228,002
	Year ended June 30, 2012:
	Revenues		$	—		$	472,390		$	23,615		$	496,005
	Depreciation and amortization			2,021			5,395			1,653			9,069
	Segment operating income (loss)			(49,231	)		237,737			(8,188	)		180,318
			Years Ended June 30,
	(In thousands)		2014			2013			2012
	Total operating income for reportable segments		$	274,442		$	228,002		$	180,318
	Unallocated amounts:
	Interest income			5,397			5,497			4,629
	Other			(1,974	)		(223	)		(407	)
	Income from operations before income taxes			277,865			233,276			184,540
	Income tax provision			101,640			86,137			72,389
	Net income		$	176,225		$	147,139		$	112,151
	The following table sets forth a comparison of balance sheet assets by operating segment:
	(In thousands)		June 30,
			2014			2013
	Net equipment and leasehold improvements:
	Research		$	8,199		$	8,590
	Molecular diagnostics			24,316			15,769
	Pharmaceutical and clinical services			2,079			3,243
	Total		$	34,594		$	27,602
	Total Assets:
	Research		$	67,999		$	82,517
	Molecular diagnostics			409,795			110,329
	Pharmaceutical and clinical services			75,434			79,911
	Total		$	553,228		$	272,757
	The following table reconciles assets by operating segment to total assets:
			June 30,
	(In thousands)		2014			2013
	Total assets by segment		$	553,228		$	272,757
	Cash, cash equivalents, and marketable investment securities (1)			270,586			531,064
	Total		$	823,814		$	803,821
		-1	The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments
	The majority of the Company’s revenues were derived from the sale of molecular diagnostic tests in the United States. There were no customers that accounted for greater than 10% of revenue in the years ended June 30, 2014, 2013 and 2012.
	Of the Company’s $169.2 million goodwill balance at June 30, 2014, $112.3 million related to Crescendo which is included in the molecular diagnostics segment and $56.9 million related to Myriad RBM which is included in the pharmaceutical and clinical services segment. Additionally, the majority of the Company’s long-lived assets are located in the United States.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	-11	Commitments and Contingencies
	The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of June 30, 2014, management of the Company believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.
	As of June 30, 2014, Crescendo Bioscience, Inc. has approximately three years remaining under an unconditional purchase obligation with a vendor to purchase goods and services used in the Company’s diagnostic processes. The agreement specifies certain minimum quantities and pricing terms.
	In addition to the minimum quantities and pricing terms, the Company may also make additional purchase commitments of anticipated purchases based upon forecasted needs which are not included in the unconditional purchase obligation amounts below.
	As of June 30, 2014, the remaining obligations under this agreement were as follows (in thousands):
			Amount
	Fiscal year ending:
	2015		$	10,863
	2016			21,262
	2017			12,142
	Total unconditional purchase obligation		$	44,267

Acquisitions

Acquisitions	12 Months Ended
	Jun. 30, 2014
Acquisitions	'
	-12	Acquisitions
	Crescendo Bioscience, Inc.
	On February 28, 2014, the Company completed the acquisition of privately-held Crescendo Bioscience, Inc. (“Crescendo”), pursuant to an Amended and Restated Agreement and Plan of Merger, dated February 2, 2014 (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Myriad acquired Crescendo for total consideration of $259 million as detailed below, by means of a reverse triangular merger in which Crescendo survived the merger as the surviving corporation and a wholly-owned subsidiary of Myriad. The surviving corporation operates under the name Crescendo Bioscience, Inc.
	The following table reconciles consideration transferred to the total cash paid to acquire Crescendo:
	(In thousands)
	Total consideration transferred		$	258,950
	Share-based compensation to Crescendo employees			6,929
	Change of control payments to Crescendo employees			5,695
	Offset: Non-cash fair value purchase option			(8,000	)
	Total cash paid		$	263,574
	The total consideration of $259 million consisted of (i) $225.1 million in cash, (ii) $25.9 million in elimination of intercompany balances related to accrued interest and the term loan the Company issued to Crescendo on September 8, 2011, and (iii) $8 million related to the fair value of the purchase option granted to the Company on September 8, 2011 by Crescendo through a definitive merger agreement (“Option Agreement”) entered into in association with the term note. Of the cash consideration, $20 million was deposited into an escrow account to fund (i) any post-closing adjustments payable to Myriad based upon differences between the estimated working capital and the actual working capital of Crescendo at closing, and (ii) any indemnification claims made by Myriad against Crescendo, for a period of time, based upon the completion of an audit of Crescendo’s financial statements, of no fewer than twelve nor more than fifteen months following closing.
	Of the total cash paid, $6.9 million was accounted for as share-based compensation expense resulting from the accelerated vesting of employee options immediately prior to the acquisition and $5.7 million was accounted for as change of control bonuses paid to Crescendo employees and directors. The Company recognized the share-based compensation expense and change of control bonuses in post-acquisition Condensed Consolidated Statements of Income for the year ended June 30, 2014.
	Total consideration transferred was allocated to tangible and identifiable intangible assets acquired and liabilities assumed based on their fair values at the acquisition date as set forth below. The Company believes that the acquisition of Crescendo facilitates the Company’s entry into the high growth autoimmune market, diversifies its product revenue and enhances its strength in protein-based diagnostics. These factors contributed to consideration transferred in excess of the fair value of Crescendo’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction. Management estimated the fair values of tangible and intangible asset and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants.
	The Company’s allocation of consideration transferred for Crescendo is as follows (in thousands):
	(In thousands)		Estimated
			Fair Value
	Other assets acquired		$	15,826
	Intangible assets			196,600
	Goodwill			112,331
	Total assets acquired			324,757
	Deferred tax liability			44,213
	Other liabilities assumed			21,594
	Total net assets acquired		$	258,950
	Identifiable Intangible Assets
	The Company acquired intangible assets that consisted of developed technology which had an estimated fair value of $165.4 million and a laboratory database with an estimated fair value of $31.2 million. The fair values of the assets were determined using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows were discounted using a discount rate of 19% which is based on the estimated internal rate of return for the acquisition and represents the rate that market participants might use to value the intangible assets. The projected cash flows were based on key assumptions such as: estimates of revenues and operating profits; the time and resources need to recreate databases and product and commercial development and approval; the life of the commercialized product; and associated risks related to viability and product alternatives. The Company will amortize the intangible assets on a straight-line basis over their estimated useful lives of 18 years. This amortization is not deductible for income tax purposes.
	Goodwill
	The $112.3 million of goodwill represents the excess of consideration transferred over the fair value of assets acquired and liabilities assumed and is attributable to the benefits expected from combining the Company’s research and commercial operations with Crescendo’s. This goodwill is not deductible for income tax purposes.
	Subsequent to the acquisition date, the Company completed a study on net operating loss tax limitations resulting in a reduction of deferred tax assets of $2.4 million that were previously recorded in conjunction with the acquisition of Crescendo. The Company determined that the adjustment related to facts and circumstances that existed at the acquisition date. As a result of this new information, the acquisition date net deferred tax liability was retrospectively increased by $2.4 million with a corresponding increase to goodwill. The adjustment did not impact the Company’s results from operations and is reflected above in the Company’s allocation of consideration transferred.
	Share-Based Compensation
	The share-based compensation expense recognized for the accelerated vesting of employee options immediately prior to the acquisition was reported in the Company’s Consolidated Statements of Comprehensive Income for the year ended June 30, 2014 as follows:
	(In thousands)
	Cost of molecular diagnostic testing		$	185
	Research and development expense			2,075
	Selling, general, and administrative expense			4,669
	Total share-based compensation		$	6,929
	Change of Control
	The change of control expense recognized for bonuses paid to Crescendo employees and directors for completion of the acquisition with Myriad was reported in the Company’s Consolidated Statements of Comprehensive Income for the year ended June 30, 2014 as follows:
	(In thousands)
	Cost of molecular diagnostic testing		$	238
	Research and development expense			1,710
	Selling, general, and administrative expense			3,747
	Total change of control bonuses		$	5,695
	Both the share-based compensation and change of control expenses are one-time items and will not impact future reporting periods.
	Other
	The Company also recorded interest income related to accretion of the note receivable that was settled at the acquisition date, for the year ended June 30, 2014 of $4.5 million, respectively, in the Consolidated Statements of Comprehensive Income. From the date of acquisition through June 30, 2014, the Company recorded Crescendo revenue of approximately $14.0 million and a net loss from Crescendo of approximately $26.0 million that included non-recurring acquisition related charges of $12.6 million.
	Pro Forma Information
	The unaudited pro-forma results presented below include the effects of the Crescendo acquisition as if it had been consummated as of July 1, 2012, with adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, stock-based compensation expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from the consolidation of Crescendo. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been consummated as of July 1, 2012.
	(In thousands)
			June 30,
			2014			2013
	Revenue		$	807,509		$	619,835
	Income from operations			252,634			177,998
	Net income		$	155,924		$	108,024
	Net income per share, basic		$	2.06		$	1.33
	Net income per share, diluted		$	1.99		$	1.3

Term_Loan

Term Loan	12 Months Ended
	Jun. 30, 2014
Term Loan	'
	-13	Term Loan
	On September 8, 2011, the Company issued a $25 million term loan to Crescendo. Under the Loan Agreement, the Company loaned Crescendo $25 million for a term of six years, with the principal due upon maturity. Interest accrued at 6% per year and is due annually. During the fiscal quarter ended September 30, 2012, the Loan Agreement was amended to increase the stated interest rate from 6% to 7% per year. On February 28, 2014, $25.9 million that represented the loan and interest outstanding was settled as an offset against the cash paid for the Crescendo acquisition.

Cost_Basis_Investment

Cost Basis Investment	12 Months Ended
	Jun. 30, 2014
Cost Basis Investment	'
	-14	Cost Basis Investment
	In April 2013, the Company acquired approximately 28 million shares of Series E preferred stock of RainDance Technologies, Inc. (“RainDance”) of Lexington, Massachusetts, for $5 million. RainDance provides high-throughput picodroplet-based technology that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The Series E shares purchased by the Company represented less than 5% of the total shares outstanding of RainDance’s capital stock. Subsequent to the investment the Company evaluated its relationship with RainDance and determined it did not have significant influence over the operations of RainDance. The Company’s investment in RainDance has been recorded under the cost method as an “Other Asset” on the Company’s consolidated balance sheet. The Company will periodically evaluate the investment for impairment. No impairment indicators were noted at June 30, 2014.

Schedule_of_Valuation_and_Qual

Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Jun. 30, 2014
Schedule of Valuation and Qualifying Accounts	'
	Schedule II
	MYRIAD GENETICS, INC.
	Schedule of Valuation and Qualifying Accounts
	Years Ended June 30, 2014, 2013, and 2012
	(In thousands)
			Balance at		Addition		Addition due to		Deductions (1)			Balance at
			Beginning		Charged to Cost		acquisition of					End of Period
			of Period		and Expenses		Crescendo
	Allowance for doubtful accounts:
	Year ended June 30, 2014		$	7,500	$	39,235		868	($	38,635	)	$	8,968
	Year ended June 30, 2013		$	4,600	$	33,294		—	($	30,394	)	$	7,500
	Year ended June 30, 2012		$	3,700	$	24,742		—	($	23,842	)	$	4,600
	-1	Represents amounts written off against the allowance.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Business Description and Basis of Presentation	'
		(a)	Business Description and Basis of Presentation
	Myriad Genetics, Inc. and subsidiaries (collectively, the Company) is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine tests. The Company employs a number of proprietary technologies, including DNA, RNA and protein analysis, that help it to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. The Company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine). The Company currently offers thirteen commercial molecular diagnostic tests, including seven predictive medicine tests, three personalized medicine tests, two prognostic medicine tests and one diagnostic medicine test. The Company also generates revenue by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters is located in Salt Lake City, Utah.
	The consolidated financial statements of the Company are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with U.S. GAAP. Certain reclassifications have been made to prior period amounts to conform to the current period presentation.
Marketable Investment Securities	'
		(b)	Marketable Investment Securities
	The Company has classified its marketable investment securities as available-for-sale. Available-for-sale investment securities with remaining maturities of greater than one year are classified as long-term. Available-for-sale investment securities with remaining maturities of less than one year are classified as short-term. Available-for-sale investment securities with remaining maturities of less than three months at the time of purchase are classified as cash equivalents. Marketable securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive (loss) in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned.
	A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against “Other income” when a decline in fair value is determined to be other than temporary. We review several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) our ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended June 30, 2014, 2013 and 2012.
Trade Accounts Receivable and Allowance for Doubtful Accounts	'
		(c)	Trade Accounts Receivable and Allowance for Doubtful Accounts
	Trade accounts receivable are comprised of amounts due from sales of the Company’s molecular diagnostic tests and pharmaceutical and clinical services and are recorded at the invoiced amount, net of discounts and contractual allowances. The allowance for doubtful accounts is based on the Company’s best estimate of the amount of probable losses in the Company’s existing accounts receivable, which is based on historical write-off experience, customer creditworthiness, facts and circumstances specific to outstanding balances, and payment terms. Account balances are charged against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.
Equipment and Leasehold Improvements	'
		(d)	Equipment and Leasehold Improvements
	Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from three to fifteen years. Repairs and maintenance costs are charged to expense as incurred. For the years ended June 30, 2014, 2013 and 2012, the Company recorded the depreciation expense as follows:
			Years Ended June 30,
			2014		2013		2012
	(In thousands)
	Depreciation expense		$	9,186	$	7,994	$	7,969
Inventory	'
		(e)	Inventory
	Inventories consist of reagents, plates and testing kits. Inventories are stated at the lower of cost or market on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels.
	The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers.
Intangible Assets and Other Long-Lived Assets	'
		(f)	Intangible Assets and Other Long-Lived Assets
	Intangible and other assets as of June 30, 2014 and 2013 are comprised of acquired patents and intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life.
	The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In December 2012, the Company notified the licensor of the Company’s OnDose product of the Company’s intent to terminate the license agreement, and as a result, recorded an impairment charge of approximately $1.5 million associated with the purchased license agreement. Other than this $1.5 million impairment charge, the Company concluded there was no impairment of long-lived assets for the years ended June 30, 2014, 2013 and 2012.
Goodwill	'
		(g)	Goodwill
	The Company has recorded goodwill of $169.2 million from the acquisition of Crescendo Bioscience, Inc. that was completed on February 28, 2014 (see Note 12) and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $112.3 million relates to the Company’s molecular diagnostic segment and $56.9 million related to the Company’s pharmaceutical and clinical services segment. Goodwill is tested for impairment on an annual basis as of April 1 and in the interim by reporting unit if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill was evaluated using a two-step process. The first step involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of the reporting unit exceeds its fair value, the second step of the process involves a comparison of the fair value and the carrying amount of the goodwill of that reporting unit. If the carrying amount of the goodwill of the reporting unit exceeds the fair value of that goodwill, an impairment loss would be recognized in an amount equal to the excess of carrying value over fair value. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.
Revenue Recognition	'
		(h)	Revenue Recognition
	Molecular diagnostic testing revenue is recognized when persuasive evidence of an agreement exists, results have been communicated to the patient, the fee is fixed or determinable, and collection is reasonably assured. Revenue from the sale of molecular diagnostic tests and related marketing agreements is recorded at the invoiced amount net of any discounts or contractual allowances.
	Pharmaceutical and clinical service revenue is recognized when persuasive evidence of an agreement exists, the fee is fixed and or determinable, when the testing service has been completed and the results of the tests are transferred to the customer, and collectability is reasonably assured. In addition, the Company’s wholly owned subsidiary, Myriad RBM, has received national, state, foreign government and private foundation grants and contracts. Revenue associated with these grants and contracts is recognized in the period in which qualifying costs for the services by the grants and contracts are incurred and the related grant or contract fee is earned.
Income Taxes	'
		(i)	Income Taxes
	The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.
	The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.
Earnings Per Share	'
		(j)	Earnings Per Share
	Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents outstanding.
	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
	(In thousands)		Years Ended June 30,
			2014		2013		2012
	Denominator:
	Weighted-average shares outstanding used to compute basic EPS			75,728		80,948		84,608
	Effect of dilutive stock options			2,454		2,379		1,857
	Weighted-average shares outstanding and dilutive securities used to compute diluted EPS			78,182		83,327		86,465
	Certain outstanding stock options were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
	(In thousands)		Years Ended June 30,
			2014		2013		2012
	Anti-dilutive options excluded from EPS computation			5,273		5,136		8,585
Use of Estimates	'
		(k)	Use of Estimates
	The preparation of the consolidated financial statements in accordance with U.S. GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of fixed assets, valuation allowances for receivables and deferred income tax assets, certain accrued liabilities, share-based compensation and impairment analysis of goodwill and intangible assets. Actual results could differ from those estimates.
Recent Accounting Pronouncements	'
		(l)	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, “Revenue from Contracts with Customers.” Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. It is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is not permitted. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. We are currently evaluating the impact, if any, the adoption of this standard will have on our Consolidated Financial Statements.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Depreciation Expense	'
	For the years ended June 30, 2014, 2013 and 2012, the Company recorded the depreciation expense as follows:
		Years Ended June 30,
		2014		2013		2012
	(In thousands)
	Depreciation expense	$	9,186	$	7,994	$	7,969
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	'
	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
	(In thousands)	Years Ended June 30,
		2014		2013		2012
	Denominator:
	Weighted-average shares outstanding used to compute basic EPS		75,728		80,948		84,608
	Effect of dilutive stock options		2,454		2,379		1,857
	Weighted-average shares outstanding and dilutive securities used to compute diluted EPS		78,182		83,327		86,465
Schedule of Anti-Dilutive Options Excluded from EPS Computation	'
	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
	(In thousands)	Years Ended June 30,
		2014		2013		2012
	Anti-dilutive options excluded from EPS computation		5,273		5,136		8,585

Marketable_Investment_Securiti1

Marketable Investment Securities (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	'
	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2014 and 2013 were as follows:
	(In thousands)	Amortized		Gross			Gross			Estimated
		cost		unrealized			unrealized			fair value
				holding			holding
				gains			losses
	At June 30, 2014:
	Cash and cash equivalents:
	Cash	$	45,181	$	—		$	—		$	45,181
	Cash equivalents		19,639		1			—			19,640
	Total cash and cash equivalents		64,820		1			—			64,821
	Available-for-sale:
	Corporate bonds and notes		44,449		36			(11	)		44,474
	Municipal bonds		137,821		334			(3	)		138,152
	Federal agency issues		23,134		12			(7	)		23,139
	Total	$	270,224	$	383		$	(21	)	$	270,586
	(In thousands)	Amortized		Gross			Gross			Estimated
		cost		unrealized			unrealized			fair value
				holding			holding
				gains			losses
	At June 30, 2013:
	Cash and cash equivalents:
	Cash	$	40,412	$	—		$	—		$	40,412
	Cash equivalents		63,653		8			—			63,661
	Total cash and cash equivalents		104,065		8			—			104,073
	Available-for-sale:
	Corporate bonds and notes		71,626		13			(15	)		71,624
	Municipal bonds		251,513		109			(537	)		251,085
	Federal agency issues		104,293		24			(35	)		104,282
	Total	$	531,497	$	154		$	(587	)	$	531,064
Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale	'
	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at June 30, 2014:
	(In thousands)	Amortized		Estimated
		cost		fair value
	Cash	$	45,181	$	45,181
	Cash equivalents		19,639		19,640
	Available-for-sale:
	Due within one year		121,505		121,641
	Due after one year through five years		83,899		84,124
	Due after five years		—		—
	Total	$	270,224	$	270,586
Schedule of Debt Securities Available-For-Sale in Gross Unrealized Loss Position	'
	Debt securities available-for-sale in a gross unrealized loss position as of June 30, 2014 and 2013 are summarized as follows:
		Less than 12 months					More than 12 months					Total
	(In thousands)	Fair		Unrealized			Fair			Unrealized		Fair		Unrealized
		value		losses			value			losses		value		losses
	At June 30, 2014:
	Debt securities:
	Corporate bonds and notes		15,961		(11	)		—			—		15,961		(11	)
	Municipal bonds		8,651		(3	)		—			—		8,651		(3	)
	Federal agency issues		4,993		(7	)		—			—		4,993		(7	)
		$	29,605	$	(21	)	$	—		$	—	$	29,605	$	(21	)
		Less than 12 months					More than 12 months					Total
	(In thousands)	Fair		Unrealized			Fair			Unrealized		Fair		Unrealized
		value		losses			value			losses		value		losses
	At June 30, 2013:
	Debt securities:
	Corporate bonds and notes		30,309		(15	)		—			—		30,309		(15	)
	Municipal bonds		93,992		(538	)		—			—		93,992		(538	)
	Federal agency issues		45,528		(34	)		—			—		45,528		(34	)
		$	169,829	$	(587	)	$	—		$	—	$	169,829	$	(587	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Fair Value of Financial Assets	'
	The following table sets forth the fair value of the Company’s financial assets that are re-measured on a regular basis:
	(In thousands)		Level 1		Level 2		Level 3		Total
	at June 30, 2014
	Money market funds (a)		$	13,634	$	—	$	—	$	13,634
	Corporate bonds and notes			—		44,474		—		44,474
	Municipal bonds			—		144,158		—		144,158
	Federal agency issues			—		23,139		—		23,139
	Total		$	13,634	$	211,771	$	—	$	225,405
	(In thousands)		Level 1		Level 2		Level 3		Total
	at June 30, 2013
	Money market funds (a)		$	12,691	$	—	$	—	$	12,691
	Corporate bonds and notes			—		71,624		—		71,624
	Municipal bonds			—		302,055		—		302,055
	Federal agency issues			—		104,282		—		104,282
	Total		$	12,691	$	477,961	$	—	$	490,652
		(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2014
Summary of Changes to Goodwill Balance	'
	The following summarizes changes to the goodwill balance for the years ended June 30, 2014 and 2013:
		Year Ended June 30,
	(In thousands)	2014		2013
	Balance at beginning of period	$	56,850	$	56,850
	Current period acquisitions		112,331		—
	Balance at end of period	$	169,181	$	56,850
Summarized Amounts Reported as Intangible Assets	'
	The following summarizes the amounts reported as intangible assets:
	(In thousands)	Gross		Accumulated			Net
		Carrying		Amortization
		Amount
	at June 30, 2014
	Purchased licenses and technologies	$	201,100	$	(6,597	)	$	194,503
	Customer relationships		4,650		(1,441	)		3,209
	Trademarks		3,000		(200	)		2,800
	Total amortized intangible assets		208,750		(8,238	)		200,512
	In-process research and development		4,800		—			4,800
	Total unamortized intangible assets		4,800		—			4,800
	Total intangible assets	$	213,550	$	(8,238	)	$	205,312
	(In thousands)	Gross		Accumulated			Net
		Carrying		Amortization
		Amount
	at June 30, 2013
	Purchased licenses and technologies	$	4,500	$	(2,644	)	$	1,856
	Customer relationships		4,650		(976	)		3,674
	Trademarks		3,000		—			3,000
	Total amortized intangible assets		12,150		(3,620	)		8,530
	In-process research and development		4,800		—			4,800
	Total unamortized intangible assets		4,800		—			4,800
	Total intangible assets	$	16,950	$	(3,620	)	$	13,330
Amortization for Intangible Assets	'
	The Company recorded amortization during the respective periods for these intangible assets as follows:
		Years Ended June 30,
	(In thousands)	2014		2013			2012
	Amortization on intangible assets	$	4,633	$	895		$	1,100
Schedule of Future Estimated Amortization Expense	'
	Future estimated amortization expense as of June 30, 2014 for the five succeeding fiscal years is as follows:
	(In thousands)
	Fiscal year ending:
	2015	$	11,900
	2016		11,900
	2017		11,900
	2018		11,881
	2019		11,587
		$	59,168

Leases_Tables

Leases (Tables)	12 Months Ended
	Jun. 30, 2014
Summary of Rental Expense	'
	The following is a summary of the Company’s rental expense for the fiscal years reported:
		Years Ended June 30,
	(In thousands)	2014		2013		2012
	Rental expense	$	11,266	$	8,155	$	6,819
Future Minimum Lease Payments	'
	Future minimum lease payments under the Company’s current leases as of June 30, 2014 are as follows:
	(In thousands)
	Fiscal year ending:
	2015	$	11,235
	2016		11,500
	2017		10,828
	2018		6,489
	2019		6,009
	Thereafter		26,191
		$	72,252

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Fair Value of Stock Option Grant Weighted-Average Assumptions	'
	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted-average assumptions used for grants for the fiscal year ended June 30:
		2014		2013	2012
	Risk-free interest rate	1.60%		0.80%	1.00%
	Expected dividend yield	0%		0%	0%
	Expected lives (in years)	4.1 - 4.7		4.2 - 4.7	4.2 - 4.6
	Expected volatility	40%		44%	44%
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding	'
	A summary of activity is as follows:
		2014						2013					2012
		Number			Weighted			Number			Weighted		Number			Weighted
		of			average			of			average		of			average
		shares			exercise			shares			exercise		shares			exercise
					price						price					price
	Options outstanding at beginning of year		14,434,970			21.75			15,233,281		$	19.32		14,453,913		$	18.22
	Options granted		3,320,553			26.52			2,957,623			27.09		3,188,160			20.42
	Less:
	Options exercised		(3,122,427	)		19.44			(3,490,495	)		15.65		(1,852,245	)		11.94
	Options canceled or expired		(394,913	)		24.3			(265,439	)		22.26		(556,547	)		21.48
	Options outstanding at end of year		14,238,183			23.3			14,434,970			21.75		15,233,281			19.32
	Options exercisable at end of year		7,149,155			21.9			7,480,472			20.51		8,397,678			18.01
	Options vested and expected to vest		13,374,736			23.12			13,543,852			21.58		14,514,637			19.28
	Weighted average fair value of options granted during the year					10.04						9.87					7.47
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding and Option Exercisable	'
	The following table summarizes information about stock options outstanding at June 30, 2014:
		Options outstanding									Options exercisable
	Range of	Number			Weighted			Weighted			Number		Weighted
	exercise	outstanding			average			average			exercisable		average
	prices	at			remaining			exercise			at		exercise
		June 30,			contractual			price			June 30,		price
		2014			life (years)						2014
	$5.89 - 19.47		4,750,203			5.85		$	17.2			3,103,525	$	16.44
	20.01 - 26.49		5,531,296			6.55			25.03			2,064,390		23.14
	26.84 - 30.34		3,929,684			7.09			28.16			1,975,740		29.17
	30.53 - 37.73		27,000			7.18			34.05			5,500		31.11
			14,238,183			6.47						7,149,155		21.9
Schedule of Share-Based Compensation Recognized in Consolidated Statements of Comprehensive Income	'
	Share-based compensation expense recognized and included in the consolidated statements of comprehensive income for the fiscal years ended June 30, 2014, 2013 and 2012 was as follows:
		Years Ended June 30,
	(In thousands)	2014			2013			2012
	Cost of molecular diagnostic testing	$	833		$	1,030		$	1,158
	Cost of pharmaceutical and clinical services		317			219			85
	Research and development expense		5,429			3,246			3,350
	Selling, general, and administrative expense		27,418			22,117			21,682
	Total share-based compensation expense	$	33,997		$	26,612		$	26,275
Schedule of Unrecognized Share-Based Compensation Cost	'
	The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, and aggregate intrinsic value of options that are fully vested is as follows:
	(In thousands)	As of
		June 30, 2014
	Unrecognized share-based compensation cost	$	41,728
	Aggregate intrinsic value of options outstanding	$	222,451
	Aggregate intrinsic value of options fully vested	$	121,659
Schedule of Intrinsic Value of Options Exercised	'
	The total intrinsic value of options exercised during 2014, 2013 and 2012 was as follows:
		Years Ended June 30,
	(In thousands)	2014			2013			2012
	Total intrinsic value of options exercised	$	49,379		$	51,785		$	21,575
Schedule of Shares Purchased and Compensation Expenses	'
	Shares purchased under and compensation expense associated with the 1995 and 2012 Plans for the years reported are as follows:
		Years Ended June 30,
	(In thousands)	2014			2013			2012
	Shares purchased under the Plans		169			149			161
	Plan compensation expense	$	1,317		$	885		$	892
Employee Stock Purchase Plan	'
Schedule of Fair Value of Stock Option Grant Weighted-Average Assumptions	'
	The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black-Scholes option-pricing model using the following weighted-average assumptions:
		2014			2013			2012
	Risk-free interest rate		0.1	%		0.1	%		0.1	%
	Expected dividend yield		0	%		0	%		0	%
	Expected lives (in years)		0.5			0.5			0.5
	Expected volatility		56	%		37	%		30	%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Stock Repurchase Programs	'
	The Company previously announced the following stock repurchase programs for its common stock:
	Date Authorized	Amount Authorized		Date Completed
	May-10	$	100,000,000	August 2010
	Aug-10	$	100,000,000	February 2011
	Mar-11	$	100,000,000	September 2011
	Aug-11	$	200,000,000	Jan-13
	Feb-13	$	200,000,000	Nov-13
	Nov-13	$	300,000,000	ongoing
	Total:	$	1,000,000,000
Schedule of Stock Repurchases	'
	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended June 30, 2014, 2013 and 2012 were as follows:
		Year ended June 30,
	(In thousands)	2014		2013		2012
	Shares purchased and retired		10,373		5,632		5,688
	Common stock and additional paid-in-capital reductions	$	82,617	$	42,679	$	42,262
	Charges to retained earnings	$	205,086	$	103,589	$	86,205

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Income Tax Expense (Benefit)	'
	Income tax expense consists of the following:
		Year ended June 30,
	(In thousands)	2014			2013			2012
	Current:
	Federal	$	97,442		$	80,333		$	67,492
	State		3,541			6,021			4,647
	Total Current		100,983			86,354			72,139
	Deferred:
	Federal		(666	)		660			(2,192	)
	State		746			(431	)		2,326
	Foreign		(2,865	)		(2,051	)		(1,735	)
	Change in valuation allowance		3,442			1,605			1,851
	Total Deferred		657			(217	)		250
	Total income tax expense	$	101,640		$	86,137		$	72,389
Schedule of Income (Loss) Before Income Taxes	'
	Income (loss) before income taxes consists of the following:
		Year ended June 30,
	(In thousands)	2014			2013			2012
	United States	$	292,081		$	243,556		$	189,702
	Foreign		(14,216	)		(10,280	)		(5,162	)
			277,865			233,276			184,540
Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported in Consolidated Statements of Operations	'
	The differences between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated statements of comprehensive income were as follows:
		Year ended June 30,
		2014			2013			2012
	Federal income tax expense at the statutory rate		35	%		35	%		35	%
	State income taxes, net of federal benefit		1.6			1.7			2.7
	Research and development credits, net of the federal tax on state credits		(0.2	)		(1.0	)		(1.3	)
	Uncertain tax positions, net of federal benefit on state positions		(0.1	)		0.2			0.2
	Incentive stock option and employee stock purchase plan expense		(0.3	)		(0.5	)		1
	Change in valuation allowance		1.2			0.7			1
	Basis difference, disposition of foreign subsidiary		(1.9	)		0			0
	Other, net		1.3			0.8			0.6
			36.6	%		36.9	%		39.2	%
Schedule of Components of Deferred Tax Assets and Liabilities	'
	The significant components of the Company’s deferred tax assets and liabilities were comprised of the following at June 30, 2014 and 2013:
		Year ended June 30,
	(In thousands)	2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	76,986		$	8,336
	Property, plant and equipment		2,947			3,103
	Accrued vacation		1,551			1,269
	Allowance for doubtful accounts		3,285			2,771
	Stock compensation expense		25,952			21,135
	Capital loss carryover		0			1,424
	Research and development credits		11,207			5,367
	Uncertain state tax positions		555			1,247
	Other, net		312			643
	Total gross deferred tax assets		122,795			45,295
	Less valuation allowance		(41,420	)		(8,218	)
	Total deferred tax assets		81,375			37,077
	Deferred tax liabilities:
	Intangible assets		71,750			438
	Total deferred tax liabilities		71,750			438
	Net deferred tax assets		9,625			36,639
	Current net deferred tax asset		6,386			8,007
	Long term net deferred tax asset		3,239			28,632
	Net deferred tax asset	$	9,625		$	36,639
Summary of Net Operating Loss and Research Credit Carryforwards	'
	At June 30, 2014, the Company had the following net operating loss and research credit carryforwards, with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated.
	(In thousands)	Amount			Subject to			Expires			through
					sections			beginning
					382, 383			in year
	Carryforwards
	Federal net operating loss	$	164,504			Yes			2027			2033
	Utah net operating loss		229,900			No			2015			2024
	California net operating loss		155,834			Yes			2016			2033
	Oklahoma net operating loss		14,142			Yes			2023			2033
	Foreign net operating losses (various jurisdictions)		27,183			No			Various			Various
	Federal research credit		3,250			Yes			2025			2032
	Utah research credit		8,296			No			2021			2028
	California research credit		2,565			Yes			n/a			n/a
Schedule of Reconciliation of Beginning and Ending Unrecognized Tax Benefits	'
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
		Year ended June 30,
	(In thousands)	2014			2013			2012
	Unrecognized tax benefits at the beginning of year	$	10,918		$	10,208		$	9,648
	Gross increases—current year tax positions		1,785			710			560
	Gross increases—prior year tax positions		350			—			—
	Gross increases—acquisitions		14,180
	Gross decreases—prior year tax positions		(2,995	)
	Unrecognized tax benefits at end of year	$	24,238		$	10,918		$	10,208
	Interest and penalties in year-end balance	$	620		$	270		$	—
Crescendo Biosciences, Inc.	'
Schedule of Components of Deferred Tax Assets and Liabilities	'
	The components of deferred tax assets, deferred tax liabilities, and the liability for unrecognized tax benefits that were included in the allocation of Crescendo’s purchase consideration are as follows:
	(In thousands)
	Deferred tax assets:
	Net operating loss carryforwards	$	70,048
	Research and development credits		5,815
	Other, net		312
	Total gross deferred tax assets		76,175
	Less valuation allowance		(29,760	)
	Total deferred tax assets		46,415
	Deferred tax liabilities:
	Intangible assets		72,005
	Stock compensation expense		4,443
	Total deferred tax liabilities		76,448
	Net deferred tax liability		30,033
	Liability for unrecognized tax benefits	$	14,180

Employee_Deferred_Savings_Plan1

Employee Deferred Savings Plan (Tables)	12 Months Ended
	Jun. 30, 2014
Recorded Contributions to Employee Deferred Savings Plan	'
	The Company’s recorded contributions to the plan as follows:
		Years ended June 30,
	(In thousands)	2014		2013		2012
	Deferred savings plan Company contributions	$	4,430	$	3,450	$	2,955

Segment_and_Related_Informatio1

Segment and Related Information (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Segment Performance Based on Income (Loss) from Continuing Operations before Interest Income and Other Income and Expense	'
	The accounting policies of the segments are the same as those described in the summary of significant accounting policies (Note 1). The Company evaluates segment performance based on income (loss) before interest income and other income and expense.
	(In thousands)		Research			Molecular			Pharmaceutical &			Total
						diagnostics			clinical services
	Year ended June 30, 2014:
	Revenues		$	—		$	748,198		$	30,018		$	778,216
	Depreciation and amortization			2,001			9,887			1,931			13,819
	Segment operating income (loss)			(64,981	)		338,020			1,403			274,442
	Year ended June 30, 2013:
	Revenues		$	—		$	582,392		$	30,773		$	613,165
	Depreciation and amortization			2,182			4,974			1,733			8,889
	Segment operating income (loss)			(56,428	)		291,509			(7,079	)		228,002
	Year ended June 30, 2012:
	Revenues		$	—		$	472,390		$	23,615		$	496,005
	Depreciation and amortization			2,021			5,395			1,653			9,069
	Segment operating income (loss)			(49,231	)		237,737			(8,188	)		180,318
			Years Ended June 30,
	(In thousands)		2014			2013			2012
	Total operating income for reportable segments		$	274,442		$	228,002		$	180,318
	Unallocated amounts:
	Interest income			5,397			5,497			4,629
	Other			(1,974	)		(223	)		(407	)
	Income from operations before income taxes			277,865			233,276			184,540
	Income tax provision			101,640			86,137			72,389
	Net income		$	176,225		$	147,139		$	112,151
Schedule Of Comparison of Balance Sheet Assets by Operating Segment	'
	The following table sets forth a comparison of balance sheet assets by operating segment:
	(In thousands)		June 30,
			2014			2013
	Net equipment and leasehold improvements:
	Research		$	8,199		$	8,590
	Molecular diagnostics			24,316			15,769
	Pharmaceutical and clinical services			2,079			3,243
	Total		$	34,594		$	27,602
	Total Assets:
	Research		$	67,999		$	82,517
	Molecular diagnostics			409,795			110,329
	Pharmaceutical and clinical services			75,434			79,911
	Total		$	553,228		$	272,757
Reconciliation of Assets by Operating Segment to Total Assets	'
	The following table reconciles assets by operating segment to total assets:
			June 30,
	(In thousands)		2014			2013
	Total assets by segment		$	553,228		$	272,757
	Cash, cash equivalents, and marketable investment securities (1)			270,586			531,064
	Total		$	823,814		$	803,821
		-1	The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2014
Summary of Remaining Unconditional Purchase Obligation	'
	As of June 30, 2014, the remaining obligations under this agreement were as follows (in thousands):
		Amount
	Fiscal year ending:
	2015	$	10,863
	2016		21,262
	2017		12,142
	Total unconditional purchase obligation	$	44,267

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2014
Reconciliation of Consideration Transferred to Total Cash Paid to Acquire Business	'
	The following table reconciles consideration transferred to the total cash paid to acquire Crescendo:
	(In thousands)
	Total consideration transferred	$	258,950
	Share-based compensation to Crescendo employees		6,929
	Change of control payments to Crescendo employees		5,695
	Offset: Non-cash fair value purchase option		(8,000	)
	Total cash paid	$	263,574
Allocation of Consideration Transferred for Crescendo	'
	The Company’s allocation of consideration transferred for Crescendo is as follows (in thousands):
	(In thousands)	Estimated
		Fair Value
	Other assets acquired	$	15,826
	Intangible assets		196,600
	Goodwill		112,331
	Total assets acquired		324,757
	Deferred tax liability		44,213
	Other liabilities assumed		21,594
	Total net assets acquired	$	258,950
Share-Based Compensation Expense Recognized for Accelerated Vesting of Employee Options	'
	The share-based compensation expense recognized for the accelerated vesting of employee options immediately prior to the acquisition was reported in the Company’s Consolidated Statements of Comprehensive Income for the year ended June 30, 2014 as follows:
	(In thousands)
	Cost of molecular diagnostic testing	$	185
	Research and development expense		2,075
	Selling, general, and administrative expense		4,669
	Total share-based compensation	$	6,929
Change of Control Expense Recognized for Bonuses Paid to Crescendo Employees and Directors	'
	The change of control expense recognized for bonuses paid to Crescendo employees and directors for completion of the acquisition with Myriad was reported in the Company’s Consolidated Statements of Comprehensive Income for the year ended June 30, 2014 as follows:
	(In thousands)
	Cost of molecular diagnostic testing	$	238
	Research and development expense		1,710
	Selling, general, and administrative expense		3,747
	Total change of control bonuses	$	5,695
Pro-forma Results of Acquisitions	'
	The unaudited pro-forma results presented below include the effects of the Crescendo acquisition as if it had been consummated as of July 1, 2012, with adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, stock-based compensation expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from the consolidation of Crescendo. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been consummated as of July 1, 2012.
	(In thousands)
		June 30,
		2014			2013
	Revenue	$	807,509		$	619,835
	Income from operations		252,634			177,998
	Net income	$	155,924		$	108,024
	Net income per share, basic	$	2.06		$	1.33
	Net income per share, diluted	$	1.99		$	1.3

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
				Molecular Diagnostics	Pharmaceutical and Clinical Services	Licensing Agreements	Equipment	Equipment	Leasehold Improvements	Leasehold Improvements
							Minimum	Maximum	Minimum	Maximum
Basis of Presentation [Line Items]	'	'	'	'	'	'	'	'	'	'
Estimated useful lives of equipment item, in years	'	'	'	'	'	'	'5 years	'7 years	'3 years	'15 years
Impairment of long-lived assets	'	'	'	'	'	$1,500,000	'	'	'	'
Goodwill	$169,181,000	$56,850,000	$56,850,000	$112,300,000	$56,900,000	'	'	'	'	'

Schedule_Of_Depreciation_Expen

Schedule Of Depreciation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Depreciation and Other Amortization Expenses [Line Items]	'	'	'
Depreciation expense	$9,186	$7,994	$7,969

Reconciliation_of_Denominators

Reconciliation of Denominators of Basic and Diluted Earnings Per Share (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]	'	'	'
Weighted-average shares outstanding used to compute basic EPS	75,728	80,948	84,608
Effect of dilutive stock options	2,454	2,379	1,857
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	78,182	83,327	86,465

Schedule_Of_AntiDilutive_Optio

Schedule Of Anti-Dilutive Options Excluded From EPS Computation (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive options excluded from EPS computation	5,273	5,136	8,585

Schedule_of_Fair_Value_for_Ava

Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Net Investment Income [Line Items]	'	'
Amortized cost	$270,224	$531,497
Gross unrealized holding gains	383	154
Gross unrealized holding losses	-21	-587
Estimated fair value	270,586	531,064
Cash	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	45,181	40,412
Estimated fair value	45,181	40,412
Cash Equivalents	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	19,639	63,653
Gross unrealized holding gains	1	8
Estimated fair value	19,640	63,661
Total Cash And Cash Equivalents	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	64,820	104,065
Gross unrealized holding gains	1	8
Estimated fair value	64,821	104,073
Corporate Bonds And Notes	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	44,449	71,626
Gross unrealized holding gains	36	13
Gross unrealized holding losses	-11	-15
Estimated fair value	44,474	71,624
Municipal Bonds	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	137,821	251,513
Gross unrealized holding gains	334	109
Gross unrealized holding losses	-3	-537
Estimated fair value	138,152	251,085
Federal Agency Issues	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	23,134	104,293
Gross unrealized holding gains	12	24
Gross unrealized holding losses	-7	-35
Estimated fair value	$23,139	$104,282

Schedule_of_Maturities_of_Debt

Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Net Investment Income [Line Items]	'	'
Amortized cost	$270,224	$531,497
Due within one year, Amortized cost	121,505	'
Due after one year through five years, Amortized cost	83,899	'
Due after five years, Amortized cost	'	'
Total	270,224	'
Estimated fair value	270,586	531,064
Due within one year, Estimated fair value	121,641	'
Due after one year through five years, Estimated fair value	84,124	'
Due after five years, Estimated fair value	'	'
Total	270,586	'
Cash	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	45,181	40,412
Estimated fair value	45,181	40,412
Cash Equivalents	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	19,639	63,653
Estimated fair value	$19,640	$63,661

Schedule_of_Debt_Securities_Av

Schedule of Debt Securities Available-For-Sale in Gross Unrealized Loss Position (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Fair Value, Less than 12 Months	$29,605	$169,829
Unrealized losses, Less than 12 months	-21	-587
Fair Value, More than 12 months	'	'
Unrealized losses, More than 12 months	'	'
Fair value, Total	29,605	169,829
Unrealized losses, Total	-21	-587
Corporate Bonds And Notes	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Fair Value, Less than 12 Months	15,961	30,309
Unrealized losses, Less than 12 months	-11	-15
Fair Value, More than 12 months	'	'
Unrealized losses, More than 12 months	'	'
Fair value, Total	15,961	30,309
Unrealized losses, Total	-11	-15
Municipal Bonds	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Fair Value, Less than 12 Months	8,651	93,992
Unrealized losses, Less than 12 months	-3	-538
Fair Value, More than 12 months	'	'
Unrealized losses, More than 12 months	'	'
Fair value, Total	8,651	93,992
Unrealized losses, Total	-3	-538
Federal Agency Issues	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Fair Value, Less than 12 Months	4,993	45,528
Unrealized losses, Less than 12 months	-7	-34
Fair Value, More than 12 months	'	'
Unrealized losses, More than 12 months	'	'
Fair value, Total	4,993	45,528
Unrealized losses, Total	($7)	($34)

Schedule_of_Fair_Value_of_Fina

Schedule of Fair Value of Financial Assets (Detail) (USD $)	Jun. 30, 2014		Jun. 30, 2013
In Thousands, unless otherwise specified
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	$225,405		$490,652
Money Market Funds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	13,634	[1]	12,691	[1]
Corporate Bonds And Notes	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	44,474		71,624
Municipal Bonds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	144,158		302,055
Federal Agency Issues	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	23,139		104,282
Level 1	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	13,634		12,691
Level 1 | Money Market Funds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	13,634	[1]	12,691	[1]
Level 2	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	211,771		477,961
Level 2 | Corporate Bonds And Notes	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	44,474		71,624
Level 2 | Municipal Bonds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	144,158		302,055
Level 2 | Federal Agency Issues	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	$23,139		$104,282
[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	12 Months Ended			1 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
				License Agreement	Trademarks	Developed Technology and Database	Customer Relationships	Purchased Licenses And Technologies
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'
Goodwill	$169,181,000	$56,850,000	$56,850,000	'	'	'	'	'
Impairment of goodwill	0	'	'	'	'	'	'	'
Estimated useful life	'	'	'	'	'14 years	'18 years	'7 years	'
Impairment charges of intangible assets	'	$1,490,000	'	$1,500,000	'	'	'	'
Weighted average remaining amortization period	'	'	'	'	'17 years	'	'17 years	'17 years

Summary_of_Changes_to_Goodwill

Summary of Changes to Goodwill Balance (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2012
Goodwill [Line Items]	'	'
Balance at beginning of period	$56,850	$56,850
Current period acquisitions	112,331	'
Balance at end of period	$169,181	$56,850

Summarized_Amounts_Reported_as

Summarized Amounts Reported as Intangible Assets (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, total intangible assets	$213,550	$16,950
Accumulated Amortization	-8,238	-3,620
Net, total intangible assets	205,312	13,330
Future estimated amortization expense, total	59,168	'
Gross Carrying Amount, non-amortizable intangible assets	4,800	4,800
Net, non-amortizable intangible assets	4,800	4,800
In-Process Research And Development	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, non-amortizable intangible assets	4,800	4,800
Net, non-amortizable intangible assets	4,800	4,800
Purchased Licenses And Technologies	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, amortizable intangible assets	201,100	4,500
Accumulated Amortization	-6,597	-2,644
Future estimated amortization expense, total	194,503	1,856
Customer Relationships	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, amortizable intangible assets	4,650	4,650
Accumulated Amortization	-1,441	-976
Future estimated amortization expense, total	3,209	3,674
Trademarks	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, amortizable intangible assets	3,000	3,000
Accumulated Amortization	-200	'
Future estimated amortization expense, total	2,800	3,000
Total amortized intangible assets	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, amortizable intangible assets	208,750	12,150
Accumulated Amortization	-8,238	-3,620
Future estimated amortization expense, total	$200,512	$8,530

Amortization_on_Intangible_Ass

Amortization on Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Finite-Lived Intangible Assets [Line Items]	'	'	'
Amortization on intangible assets	$4,633	$895	$1,100

Schedule_Of_Future_Estimated_A

Schedule Of Future Estimated Amortization Expense (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Acquired Finite-Lived Intangible Assets [Line Items]	'
2015	$11,900
2016	11,900
2017	11,900
2018	11,881
2019	11,587
Future estimated amortization expense, total	$59,168

Leases_Additional_Information_

Leases - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2014
	Leases
Myriad RBM	'
Leases [Line Items]	'
Non-cancelable operating leases	2
Myriad RBM | Minimum	'
Leases [Line Items]	'
Operating leases expiration period	'2017
Myriad RBM | Maximum	'
Leases [Line Items]	'
Operating leases expiration period	'2020
Administrative Functions | Minimum	'
Leases [Line Items]	'
Operating leases expiration period	'2013
Administrative Functions | Maximum	'
Leases [Line Items]	'
Operating leases expiration period	'2018
Information Technology Equipment	'
Leases [Line Items]	'
Non-cancelable operating leases	2
Information Technology Equipment | Minimum	'
Leases [Line Items]	'
Operating leases expiration period	'2016
Salt Lake City, Utah	'
Leases [Line Items]	'
Non-cancelable operating leases	5
Salt Lake City, Utah | Minimum	'
Leases [Line Items]	'
Operating leases expiration period	'2017
Salt Lake City, Utah | Maximum	'
Leases [Line Items]	'
Operating leases expiration period	'2025
Munich, Germany	'
Leases [Line Items]	'
Cancelable operating leases	1
Lease term	'5 years
South San Francisco, California	'
Leases [Line Items]	'
Non-cancelable operating leases	1
Operating leases expiration period	'2017

Summary_of_Rental_Expense_Deta

Summary of Rental Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Operating Leased Assets [Line Items]	'	'	'
Rental expense	$11,266	$8,155	$6,819

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Operating Leased Assets [Line Items]	'
2015	$11,235
2016	11,500
2017	10,828
2018	6,489
2019	6,009
Thereafter	26,191
Total	$72,252

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 05, 2013

Jun. 30, 2014

Dec. 05, 2012

Dec. 05, 2012

Jun. 30, 2014

Dec. 05, 2012

Options granted after December 5, 2012

Options granted prior to December 5, 2012

Cost Of Molecular Diagnostic Testing

Cost Of Molecular Diagnostic Testing

Cost Of Molecular Diagnostic Testing

Research And Development Expense

Research And Development Expense

Research And Development Expense

Selling, General, and Administrative Expenses

Selling, General, and Administrative Expenses

Selling, General, and Administrative Expenses

Crescendo Biosciences, Inc.

Crescendo Biosciences, Inc.

Crescendo Biosciences, Inc.

The 2010 Plan

The 2010 Plan

The 2010 Plan

1995 Purchase Plan

1995 Purchase Plan

2012 Purchase Plan

2012 Purchase Plan

Cost Of Molecular Diagnostic Testing

Research And Development Expense

Selling, General, and Administrative Expenses

Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares approved

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

2,000,000

'

2,000,000

Shares reserved for issuance exercise of options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,757,381

'

'

'

'

'

'

Shares available for future grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,005,532

'

'

'

'

Service period of option vested, years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

Options expire from date of grant, years

'

'

'

'8 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable, weighted average remaining contractual life

'5 years 6 months 22 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total share-based compensation expense

$33,997

$26,612

$26,275

'

'

$833

$1,030

$1,158

$5,429

$3,246

$3,350

$27,418

$22,117

$21,682

$200

$2,000

$4,700

'

'

'

'

'

'

'

Total unrecognized share-based compensation cost, weighted-average period, years

'2 years 3 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares purchased under the Plan

169,000

149,000

161,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,990,000

'

169,000

'

Schedule_of_Fair_Value_of_Stoc

Schedule of Fair Value of Stock Option Grant with Weighted-Average Assumptions (Detail)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Options Plan	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	1.60%	0.80%	1.00%
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	40.00%	44.00%	44.00%
Options Plan | Minimum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected lives (in years)	'4 years 1 month 6 days	'4 years 2 months 12 days	'4 years 2 months 12 days
Options Plan | Maximum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected lives (in years)	'4 years 8 months 12 days	'4 years 8 months 12 days	'4 years 7 months 6 days
Employee Stock Purchase Plan	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	0.10%	0.10%	0.10%
Expected dividend yield	0.00%	0.00%	0.00%
Expected lives (in years)	'6 months	'6 months	'6 months
Expected volatility	56.00%	37.00%	30.00%

Schedule_of_ShareBased_Compens

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Options outstanding at beginning of year, Number of shares	14,434,970	15,233,281	14,453,913
Options granted, Number of shares	3,320,553	2,957,623	3,188,160
Options exercised, Number of shares	-3,122,427	-3,490,495	-1,852,245
Options canceled or expired, Number of shares	-394,913	-265,439	-556,547
Options outstanding at end of year, Number of shares	14,238,183	14,434,970	15,233,281
Options exercisable at end of year, Number of shares	7,149,155	7,480,472	8,397,678
Options vested and expected to vest, Number of shares	13,374,736	13,543,852	14,514,637
Options outstanding at beginning of year, Weighted average exercise price	$21.75	$19.32	$18.22
Options granted, Weighted average exercise price	$26.52	$27.09	$20.42
Options exercised, Weighted average exercise price	$19.44	$15.65	$11.94
Options canceled or expired, Weighted average exercise price	$24.30	$22.26	$21.48
Options outstanding at end of year, Weighted average exercise price	$23.30	$21.75	$19.32
Options exercisable at end of year, Weighted average exercise price	$21.90	$20.51	$18.01
Options vested and expected to vest, Weighted average exercise price	$23.12	$21.58	$19.28
Weighted average fair value of options granted during the year	$10.04	$9.87	$7.47

Recovered_Sheet1

Schedule Of Share-Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Options Exercisable (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number outstanding at June 30,2013, Option outstanding	14,238,183
Weighted average remaining contractual life (years), Options outstanding	'6 years 5 months 19 days
Number exercisable at June 30, 2013, Options exercisable	7,149,155
Weighted average exercise price, Options exercisable	$21.90
$ 5.89 - 19.47	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of exercise prices, minimum	$5.89
Range of exercise prices, maximum	$19.47
Number outstanding at June 30,2013, Option outstanding	4,750,203
Weighted average remaining contractual life (years), Options outstanding	'5 years 10 months 6 days
Weighted average exercise price, Options outstanding	$17.20
Number exercisable at June 30, 2013, Options exercisable	3,103,525
Weighted average exercise price, Options exercisable	$16.44
$ 20.01 - 26.49	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of exercise prices, minimum	$20.01
Range of exercise prices, maximum	$26.49
Number outstanding at June 30,2013, Option outstanding	5,531,296
Weighted average remaining contractual life (years), Options outstanding	'6 years 6 months 18 days
Weighted average exercise price, Options outstanding	$25.03
Number exercisable at June 30, 2013, Options exercisable	2,064,390
Weighted average exercise price, Options exercisable	$23.14
$ 26.84 - 30.34	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of exercise prices, minimum	$26.84
Range of exercise prices, maximum	$30.34
Number outstanding at June 30,2013, Option outstanding	3,929,684
Weighted average remaining contractual life (years), Options outstanding	'7 years 1 month 2 days
Weighted average exercise price, Options outstanding	$28.16
Number exercisable at June 30, 2013, Options exercisable	1,975,740
Weighted average exercise price, Options exercisable	$29.17
$ 30.53 - 37.73	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of exercise prices, minimum	$30.53
Range of exercise prices, maximum	$37.73
Number outstanding at June 30,2013, Option outstanding	27,000
Weighted average remaining contractual life (years), Options outstanding	'7 years 2 months 5 days
Weighted average exercise price, Options outstanding	$34.05
Number exercisable at June 30, 2013, Options exercisable	5,500
Weighted average exercise price, Options exercisable	$31.11

Schedule_of_ShareBased_Compens1

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Comprehensive Income (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total share-based compensation expense	$33,997	$26,612	$26,275
Cost Of Molecular Diagnostic Testing	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total share-based compensation expense	833	1,030	1,158
Cost of Pharmaceutical and Clinical Services	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total share-based compensation expense	317	219	85
Research And Development Expense	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total share-based compensation expense	5,429	3,246	3,350
Selling, General, and Administrative Expenses	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total share-based compensation expense	$27,418	$22,117	$21,682

Schedule_Of_Unrecognized_Share

Schedule Of Unrecognized Share-Based Compensation Cost (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized share-based compensation cost	$41,728
Aggregate intrinsic value of options outstanding	222,451
Aggregate intrinsic value of options fully vested	$121,659

Schedule_Of_Intrinsic_Value_Of

Schedule Of Intrinsic Value Of Options Exercised (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total intrinsic value of options exercised	$49,379	$51,785	$21,575

Schedule_Of_Shares_Purchased_A

Schedule Of Shares Purchased And Compensation Expenses (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares purchased under the Plans	169	149	161
Plan compensation expense	$1,317	$885	$892

Schedule_Of_Stock_Repurchase_P

Schedule Of Stock Repurchase Program (Detail) (USD $)	1 Months Ended
	Nov. 30, 2013	Feb. 28, 2013	Aug. 31, 2011	Mar. 31, 2011	Aug. 31, 2010	31-May-10	Jun. 30, 2014
Stockholders Equity [Line Items]	'	'	'	'	'	'	'
Date Authorized	'2013-11	'2013-02	'2011-08	'2011-03	'2010-08	'2010-05	'
Amount Authorized	$300,000,000	$200,000,000	$200,000,000	$100,000,000	$100,000,000	$100,000,000	$1,000,000,000
Date Completed	'	'2013-11	'2013-01	'2011-09	'2011-02	'2010-08	'
Date Completed	'ongoing	'	'	'	'	'	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	Jun. 30, 2014	Nov. 30, 2013	Feb. 28, 2013	Aug. 31, 2011	Mar. 31, 2011	Aug. 31, 2010	31-May-10	Nov. 30, 2013	Jun. 30, 2014	Nov. 30, 2013
								Fifth Share Repurchase Program	Sixth Share Repurchase Program	Sixth Share Repurchase Program
Stockholders Equity Note [Line Items]	'	'	'	'	'	'	'	'	'	'
Share repurchase program, authorized amount	$1,000,000,000	$300,000,000	$200,000,000	$200,000,000	$100,000,000	$100,000,000	$100,000,000	$200,000,000	'	$300,000,000
Shares repurchased	'	'	'	'	'	'	'	$153,000,000	$134,000,000	'

Schedule_of_Stock_Repurchases_

Schedule of Stock Repurchases (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Stockholders Equity [Line Items]	'	'	'
Common stock and additional paid-in-capital reductions	$82,617	$42,679	$42,262
Charges to retained earnings	$205,086	$103,589	$86,205
Common Stock	'	'	'
Stockholders Equity [Line Items]	'	'	'
Shares purchased and retired	10,373	5,632	5,688

Schedule_Of_Income_Tax_Expense

Schedule Of Income Tax Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Taxes [Line Items]	'	'	'
Current, Federal	$97,442	$80,333	$67,492
Current, State	3,541	6,021	4,647
Total Current	100,983	86,354	72,139
Deferred, Federal	-666	660	-2,192
Deferred, State	746	-431	2,326
Foreign	-2,865	-2,051	-1,735
Change in valuation allowance	3,442	1,605	1,851
Total Deferred	657	-217	250
Total income tax expense	$101,640	$86,137	$72,389

Schedule_Of_Income_Loss_Before

Schedule Of Income (Loss) Before Income Taxes Consists Of Following (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax [Line Items]	'	'	'
Income (loss) before income taxes, United States	$292,081	$243,556	$189,702
Income (loss) before income taxes, Foreign	-14,216	-10,280	-5,162
Income before income taxes	$277,865	$233,276	$184,540

Schedule_Of_Differences_Betwee

Schedule Of Differences Between Income Taxes At Statutory Federal Rate And Income Taxes Reported In Consolidated Statements of Comprehensive Income (Detail)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Rate Reconciliation [Line Items]	'	'	'
Federal income tax expense at the statutory rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	1.60%	1.70%	2.70%
Research and development credits, net of the federal tax on state credits	-0.20%	-1.00%	-1.30%
Uncertain tax positions, net of federal benefit on state positions	-0.10%	0.20%	0.20%
Incentive stock option and employee stock purchase plan expense	-0.30%	-0.50%	1.00%
Change in valuation allowance	1.20%	0.70%	1.00%
Basis difference, disposition of foreign subsidiary	-1.90%	0.00%	0.00%
Other, net	1.30%	0.80%	0.60%
Effective income tax rate, continuing operations, total	36.60%	36.90%	39.20%

Schedule_Of_Significant_Compon

Schedule Of Significant Components of Company's Deferred Tax Assets And Liabilities Comprised of Following (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Net operating loss carryforwards	$76,986	$8,336
Property, plant and equipment	2,947	3,103
Accrued vacation	1,551	1,269
Allowance for doubtful accounts	3,285	2,771
Stock compensation expense	25,952	21,135
Capital loss carryover	0	1,424
Research and development credits	11,207	5,367
Uncertain state tax positions	555	1,247
Other, net	312	643
Total gross deferred tax assets	122,795	45,295
Less valuation allowance	-41,420	-8,218
Total deferred tax assets	81,375	37,077
Deferred tax liabilities:	'	'
Intangible assets	71,750	438
Total deferred tax liabilities	71,750	438
Net deferred tax assets	9,625	36,639
Current net deferred tax asset	6,386	8,007
Long term net deferred tax asset	3,239	28,632
Net deferred tax asset	$9,625	$36,639

Components_of_Deferred_Tax_Ass

Components of Deferred Tax Assets, Deferred Tax Liabilities, and Liability for Unrecognized Tax Benefits Included in Allocation of Crescendo's Purchase Consideration (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Feb. 28, 2014
			Crescendo Biosciences, Inc.
Deferred tax assets:	'	'	'
Net operating loss carryforwards	$76,986,000	$8,336,000	$70,048,000
Research and development credits	11,207,000	5,367,000	5,815,000
Other, net	312,000	643,000	312,000
Total gross deferred tax assets	122,795,000	45,295,000	76,175,000
Less valuation allowance	-41,420,000	-8,218,000	-29,760,000
Total deferred tax assets	81,375,000	37,077,000	46,415,000
Deferred tax liabilities:	'	'	'
Intangible assets	71,750,000	438,000	72,005,000
Stock compensation expense	'	'	4,443,000
Total deferred tax liabilities	71,750,000	438,000	76,448,000
Net deferred tax liability	'	'	30,033,000
Liability for unrecognized tax benefits	$24,238,000	$10,718,000	$14,180,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Feb. 28, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
			Psynova	Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.	Utah	Utah	Foreign (various jurisdictions)
							Prior to the adoption of Statement 123(R)
Income Taxes [Line Items]	'	'	'	'	'	'	'	'
Amount of valuation allowance increased	$33,202,000	$1,605,000	'	$29,760,000	'	'	'	$3,442,000
Excess tax benefits realized	7,122,000	7,888,000	'	'	'	'	'	'
Excess tax benefits attributable to deferred tax asset	76,986,000	8,336,000	'	'	70,048,000	92,557,000	3,008,000	'
Remaining excess tax benefits not included in deferred tax assets	'	'	'	'	'	137,343,000	'	'
Valuation allowance to offset foreign and miscellaneous state net operating loss carry-forwards	3,786,000	'	'	'	'	'	'	'
Taxable loss of disposition of asset	'	'	15,200,000	'	'	'	'	'
Cumulative effect	$0	'	'	'	'	'	'	'
Income tax returns examination	'The Company's New York State income tax returns for the years ended June 30, 2011, 2012 and 2013 were under examination by the New York State Department of Taxation and Finance.	'	'	'	'	'	'	'

Summary_of_Net_Operating_Loss_

Summary of Net Operating Loss and Research Credit Carryforwards (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Domestic Country | Federal	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses	$164,504
Net operating losses subject to sections 382,383	'Yes
Domestic Country | Federal | Research	'
Operating Loss Carryforwards [Line Items]	'
Research credit	3,250
Research credit subject to sections 382,383	'Yes
State and Local Jurisdiction | UTAH	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses	229,900
Net operating losses subject to sections 382,383	'No
State and Local Jurisdiction | UTAH | Research	'
Operating Loss Carryforwards [Line Items]	'
Research credit	8,296
Research credit subject to sections 382,383	'No
State and Local Jurisdiction | South San Francisco, California	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses	155,834
Net operating losses subject to sections 382,383	'Yes
State and Local Jurisdiction | South San Francisco, California | Research	'
Operating Loss Carryforwards [Line Items]	'
Research credit	2,565
Research credit subject to sections 382,383	'Yes
State and Local Jurisdiction | OKLAHOMA	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses	14,142
Net operating losses subject to sections 382,383	'Yes
Foreign (various jurisdictions)	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses	$27,183
Net operating losses subject to sections 382,383	'No
Minimum | Domestic Country | Federal	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2027
Minimum | Domestic Country | Federal | Research	'
Operating Loss Carryforwards [Line Items]	'
Research credit, expiration in year	'2025
Minimum | State and Local Jurisdiction | UTAH	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2015
Minimum | State and Local Jurisdiction | UTAH | Research	'
Operating Loss Carryforwards [Line Items]	'
Research credit, expiration in year	'2021
Minimum | State and Local Jurisdiction | South San Francisco, California	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2016
Minimum | State and Local Jurisdiction | OKLAHOMA	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2023
Minimum | Foreign (various jurisdictions)	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration date ranges	'Various
Maximum | Domestic Country | Federal	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2033
Maximum | Domestic Country | Federal | Research	'
Operating Loss Carryforwards [Line Items]	'
Research credit, expiration in year	'2032
Maximum | State and Local Jurisdiction | UTAH	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2024
Maximum | State and Local Jurisdiction | UTAH | Research	'
Operating Loss Carryforwards [Line Items]	'
Research credit, expiration in year	'2028
Maximum | State and Local Jurisdiction | South San Francisco, California	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2033
Maximum | State and Local Jurisdiction | OKLAHOMA	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration in year	'2033
Maximum | Foreign (various jurisdictions)	'
Operating Loss Carryforwards [Line Items]	'
Net operating losses, expiration date ranges	'Various

Schedule_Of_Reconciliation_Of_

Schedule Of Reconciliation Of Beginning And Ending Amount Of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Reconciliation [Line Items]	'	'	'
Unrecognized tax benefits at the beginning of year	$10,918	$10,208	$9,648
Gross increases-current year tax positions	1,785	710	560
Gross increases-prior year tax positions	350	'	'
Gross increases-acquisitions	14,180	'	'
Gross decreases-prior year tax positions	-2,995	'	'
Unrecognized tax benefits at end of year	24,238	10,918	10,208
Interest and penalties in year-end balance	$620	$270	'

Employee_Deferred_Savings_Plan2

Employee Deferred Savings Plan - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2014
Savings Plan [Line Items]	'
Percent of employee contribution to deferred savings plan	50.00%
Employer's contribution not to exceed percentage of the employees compensation	4.00%

Companys_Recorded_Contribution

Company's Recorded Contributions To Plan (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Savings Plan [Line Items]	'	'	'
Deferred savings plan Company contributions	$4,430	$3,450	$2,955

Segment_and_Related_Informatio2

Segment and Related Information - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]	'	'	'
Number of reportable segment	3	'	'
Goodwill	169,181	56,850	56,850
Molecular Diagnostics	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Goodwill	112,300	'	'
Pharmaceutical and Clinical Services	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Goodwill	56,900	'	'
Customer Concentration Risk	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Concentration risk, percentage of revenue	10.00%	10.00%	10.00%

Segment_Performance_Based_on_I

Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]	'	'	'
Revenues	$778,216	$613,165	$496,005
Depreciation and amortization	13,819	8,889	9,069
Segment operating income (loss)	274,442	228,002	180,318
Research	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Depreciation and amortization	2,001	2,182	2,021
Segment operating income (loss)	-64,981	-56,428	-49,231
Molecular Diagnostics	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	748,198	582,392	472,390
Depreciation and amortization	9,887	4,974	5,395
Segment operating income (loss)	338,020	291,509	237,737
Pharmaceutical and Clinical Services	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	30,018	30,773	23,615
Depreciation and amortization	1,931	1,733	1,653
Segment operating income (loss)	$1,403	($7,079)	($8,188)

Schedule_of_Total_Operating_In

Schedule of Total Operating Income for Continuing Reportable Segments (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]	'	'	'
Total operating income for reportable segments	$274,442	$228,002	$180,318
Interest income	5,397	5,497	4,629
Other	-1,974	-223	-407
Income before income taxes	277,865	233,276	184,540
Income tax provision	101,640	86,137	72,389
Net income	$176,225	$147,139	$112,151

Schedule_Of_Comparison_Of_Bala

Schedule Of Comparison Of Balance Sheet Assets By Operating Segment (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'
Net equipment and leasehold improvements	$34,594	$27,602
Total assets by segment	823,814	803,821
Operating Segments	'	'
Segment Reporting Information [Line Items]	'	'
Net equipment and leasehold improvements	34,594	27,602
Total assets by segment	553,228	272,757
Operating Segments | Research	'	'
Segment Reporting Information [Line Items]	'	'
Net equipment and leasehold improvements	8,199	8,590
Total assets by segment	67,999	82,517
Operating Segments | Molecular Diagnostics	'	'
Segment Reporting Information [Line Items]	'	'
Net equipment and leasehold improvements	24,316	15,769
Total assets by segment	409,795	110,329
Operating Segments | Pharmaceutical and Clinical Services	'	'
Segment Reporting Information [Line Items]	'	'
Net equipment and leasehold improvements	2,079	3,243
Total assets by segment	$75,434	$79,911

Reconciliation_of_Assets_by_Op

Reconciliation of Assets by Operating Segment to Total Assets (Detail) (USD $)	Jun. 30, 2014		Jun. 30, 2013
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'		'
Assets	$823,814		$803,821
Operating Segments	'		'
Segment Reporting, Asset Reconciling Item [Line Items]	'		'
Assets	553,228		272,757
Cash, cash equivalents, and marketable investment securities	'		'
Segment Reporting, Asset Reconciling Item [Line Items]	'		'
Assets	$270,586	[1]	$531,064	[1]
[1]	The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments

Summary_of_Remaining_Unconditi

Summary of Remaining Unconditional Purchase Obligation (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Unrecorded Unconditional Purchase Obligation [Line Items]	'
Unconditional purchase obligation, 2015	$10,863
Unconditional purchase obligation, 2016	21,262
Unconditional purchase obligation, 2017	12,142
Total unconditional purchase obligation	$44,267

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended	4 Months Ended	12 Months Ended				0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Feb. 28, 2014	Jun. 30, 2014	Jun. 30, 2014	Feb. 28, 2014	Feb. 28, 2014	Feb. 28, 2014	Feb. 28, 2014	Feb. 28, 2014
				Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.	Crescendo Biosciences, Inc.
								Developed Technology	Database	Minimum	Maximum
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total consideration transferred	'	'	'	$258,950,000	'	'	'	'	'	'	'
Business acquisition, cash transferred	223,531,000	'	'	225,100,000	'	'	'	'	'	'	'
Elimination of intercompany balances related to accrued interest and term loan	'	'	'	25,900,000	'	'	'	'	'	'	'
Fair value of purchase option granted	'	'	'	8,000,000	'	'	'	'	'	'	'
Business acquisition, amount deposited into escrow account	'	'	'	20,000,000	'	'	'	'	'	'	'
Period of audit completion	'	'	'	'	'	'	'	'	'	'12 months	'15 months
Share-based compensation to Crescendo employees	'	'	'	6,929,000	'	'	'	'	'	'	'
Control bonuses paid to Crescendo employees	'	'	'	5,695,000	'	'	'	'	'	'	'
Intangible assets	'	'	'	'	'	'	196,600,000	165,400,000	31,200,000	'	'
Discount rate of estimated net cash flows	'	'	'	19.00%	'	'	'	'	'	'	'
Estimated useful lives of intangible assets, years	'	'	'	'18 years	'	'	'	'	'	'	'
Goodwill	169,181,000	56,850,000	56,850,000	'	'	'	112,331,000	'	'	'	'
Interest income related to accretion of the note receivable	'	'	'	'	'	4,500,000	'	'	'	'	'
Revenue	778,216,000	613,165,000	496,005,000	'	14,000,000	'	'	'	'	'	'
Net loss	176,225,000	147,139,000	112,151,000	'	26,000,000	'	'	'	'	'	'
Non-recurring acquisition related charges	'	'	'	'	$12,600,000	'	'	'	'	'	'

Reconciliation_of_Consideratio

Reconciliation of Consideration Transferred to Total Cash Paid to Acquire Business (Detail) (Crescendo Biosciences, Inc., USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2014
Crescendo Biosciences, Inc.	'
Schedule of Business Acquisitions, Cost of Acquired Entity [Line Items]	'
Total consideration transferred	$258,950
Share-based compensation to Crescendo employees	6,929
Change of control payments to Crescendo employees	5,695
Offset: Non-cash fair value purchase option	-8,000
Total cash paid	$263,574

Allocation_of_Consideration_Tr

Allocation of Consideration Transferred for Crescendo (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Feb. 28, 2014
In Thousands, unless otherwise specified				Crescendo Biosciences, Inc.
Business Acquisition [Line Items]	'	'	'	'
Other assets acquired	'	'	'	$15,826
Intangible assets	'	'	'	196,600
Goodwill	169,181	56,850	56,850	112,331
Total assets acquired	'	'	'	324,757
Deferred tax liability	'	'	'	44,213
Other liabilities assumed	'	'	'	21,594
Total net assets acquired	'	'	'	$258,950

Sharebased_Compensation_Expens

Share-based Compensation Expense Recognized for the Accelerated Vesting of Employee Options (Detail) (Crescendo Biosciences, Inc., USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2014
Acquisitions [Line Items]	'
Share-based compensation	$6,929
Cost Of Molecular Diagnostic Testing	'
Acquisitions [Line Items]	'
Share-based compensation	185
Research And Development Expense	'
Acquisitions [Line Items]	'
Share-based compensation	2,075
Selling, General, and Administrative Expenses	'
Acquisitions [Line Items]	'
Share-based compensation	$4,669

Change_of_Control_Expense_Reco

Change of Control Expense Recognized for Bonuses Paid to Crescendo Employees (Detail) (Crescendo Biosciences, Inc., USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2014
Business Acquisition [Line Items]	'
Change of control bonuses	$5,695
Cost Of Molecular Diagnostic Testing	'
Business Acquisition [Line Items]	'
Change of control bonuses	238
Research And Development Expense	'
Business Acquisition [Line Items]	'
Change of control bonuses	1,710
Selling, General, and Administrative Expenses	'
Business Acquisition [Line Items]	'
Change of control bonuses	$3,747

Proforma_Results_of_Acquisitio

Pro-forma Results of Acquisitions (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Business Acquisition, Pro Forma Information [Line Items]	'	'
Revenue	$807,509	$619,835
Income from operations	252,634	177,998
Net income	$155,924	$108,024
Net income per share, basic	$2.06	$1.33
Net income per share, diluted	$1.99	$1.30

Term_Loan_Additional_Informati

Term Loan - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2014	Sep. 30, 2012	Jun. 30, 2014	Sep. 08, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'
Loan Agreement, principal amount	'	'	'	$25
Term of loan, in years	'	'	'6 years	'
Interest rate per annum	'	7.00%	6.00%	'
Loan and interest outstanding, settled	$25.90	'	'	'

Cost_Basis_Investment_Addition

Cost Basis Investment - Additional Information (Detail) (RainDance, Series E Preferred Stock, USD $)	1 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2013
Schedule of Cost-method Investments [Line Items]	'
Shares acquired	28
Value of shares acquired	$5
Maximum	'
Schedule of Cost-method Investments [Line Items]	'
Percentage of total shares outstanding acquired	5.00%

Schedule_of_Valuation_and_Qual1

Schedule of Valuation and Qualifying Accounts (Detail) (Allowance for Doubtful Accounts, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2012
Allowance for Doubtful Accounts	'		'		'
Valuation and Qualifying Accounts Disclosure [Line Items]	'		'		'
Balance at Beginning of Period	$7,500		$4,600		$3,700
Addition Changed to Cost and Expenses	39,235		33,294		24,742
Addition due to acquisition of Crescendo	868		'		'
Deductions	-38,635	[1]	-30,394	[1]	-23,842	[1]
Balance at End of Period	$8,968		$7,500		$4,600
[1]	Represents amounts written off against the allowance.